Georgian Scientists
ქართველი მეცნიერები
Vol. 7 Issue 3, 2025
https://doi.org/10.52340/gs.2025.07.03.25

THE SCIENTIFIC DISCUSSION OF KEY ISSUE ASPECTS OF MITOCHONDRIAL DYSFUNCTION AND PHARMACOTHERAPEUTIC MANAGEMENT STRATEGIES IN PARKINSON'S DISEASE: FOCUS ON MITOPHAGY AND NAD+ METABOLISM

Nodar Sulashvili[1], Elene Abzianidze[2], Margarita Beglaryan[3], Luiza Gabunia[4], Nana Gorgaslidze[5], Nato Alavidze[6], Tharaka Srinatha Dunuwila[7], Kshitij Kumar[8], Jugal Kishore[9], Ketevan Ghambashidze[10], Marika Sulashvili[11], Lela Grigolia[12], Kakhaber Robakidze[13], Irine Zarnadze[14], Shalva (Davit) Zarnadze[15], David Aphkhazava[16]

[1]MD, PhD, Doctor of Pharmaceutical and Pharmacological Sciences in Medicine, Invited Lecturer (Invited Professor) of Scientific Research-Skills Center at Tbilisi State Medical University; Professor of Medical and Clinical Pharmacology of International School of Medicine at Alte University; Professor of Pharmacology of Faculty of Medicine at Georgian National University SEU; Tbilisi, Georgia; Orcid https://orcid.org/0000-0002-9005-8577; E-mail: n.sulashvili@ug.edu.ge

[2]PhD, Doctor of Biological Sciences, Academician, Emeritus Professor of Tbilisi State Medical University, Department of Molecular and Medical Genetics; Tbilisi, Georgia.

[3]MD, PhD, Doctor of Pharmaceutical Sciences, Academician, Professor of Yerevan State Medical University After Mkhitar Heratsi, Head of the Department of Pharmaceutical Management, President of Association PHESA (Pharmacy and Pharmacology Education and Science Association), Yerevan, Armenia; https://orcid.org/0000-0003-3697-6390

[4]MD, PhD, Doctor of Medical Sciences, Professor, Director of the Scientific Research-Skills Center at Tbilisi State Medical University, Professor, Head of the Department of Medical and Clinical Pharmacology at Tbilisi State Medical University, Clinical Pharmacologist of The First University Clinic of TSMU, Tbilisi, Georgia https://orcid.org/0000-0003-0856-2684

[5]MD, PhD, Doctor of Pharmaceutical Sciences, Academician, Professor of Tbilisi State Medical University, Head of The Department of Social and Clinical Pharmacy, Tbilisi, Georgia. https://orcid.org/0000-0002-4563-5224

[6]MD, PhD, Doctor of Pharmaceutical Sciences, Professor of Akaki Tsereteli State University, Faculty of Medicine, Department of Pharmacy, Kutaisi, Georgia. Professor, Dean Faculty of Medicine at East European University, Tbilisi, Georgia. https://orcid.org/0000-0001-6695-5924

[7]MD, PhD, Associate Professor of International School of Medicine at Alte University; Tbilisi, Georgia

[8]MD, PGCDM, Diploma (Clinical Nephrology) Department of Nephrology (St Stephen's hospital) Delhi; New Delhi India.

[9]Laboratory of Brain Ultrastructure and Nanoarchitecture, Ivane Beritashvili Center of Experimental Biomedicine, Tbilisi, Georgia; MD student of Department of Medicine, Georgian National University SEU, Tbilisi, Georgia.

[10]MD, PhD, Doctor of Medical Sciences, Invited Professor of the Scientific Research Skills Center of Tbilisi State Medical University, Professor of Pathophysiology Department at Tbilisi State Medical University; Tbilisi, Georgia. https://orcid.org/0000-0002-3845-9306

[11]MD, Doctor of Family Medicine, Invited Lecturer of Tbilisi State Medical University, Department of Molecular and Medical Genetics, Invited Professor of Biochemistry and Molecular and Medical Genetics at The University of Georgia; Tbilisi, Georgia.
[12]MD, PhD, Doctor of Medical Sciences, Professor of Faculty of Medicine at Caucasus International University; Tbilisi, Georgia;
[13]MD, PhD, Doctor of Medical Sciences, Academician, Professor of Faculty of Medicine at Caucasus International University; Doctor-Professor of National Health Center Named After Academician O. Gudushauri; Tbilisi, Georgia;
[14]MD, PhD, Doctor of Medical Sciences, Professor of Tbilisi State Medical University, Department of Public Health, Health Care Management, Policy and Economy, Tbilisi, Georgia.
[15]MD, PhD, Doctor of Medical Sciences, Academician, Professor of Tbilisi State Medical University, Dean of the Faculty of Public Health, Head of the Department of Nutrition, Aging Medicine, Environmental and Occupational Health, Tbilisi, Georgia.
[16]PhD, Doctor of Biological Sciences, Professor of International School of Medicine at Alte University, Tbilisi, Georgia;

Corresponding Author: Dr. Professor Nodar Sulashvili
Mail: n.sulashvili@ug.edu.ge
Mob: +995-597-12-17-28

ABSTRACT

Parkinson's disease (PD) is a prevalent neurodegenerative disorder characterized by the progressive loss of dopaminergic neurons and the accumulation of α-synuclein in Lewy bodies. Mitochondrial dysfunction plays a central role in both sporadic and familial PD, contributing to bioenergetic deficits, oxidative stress, and mitochondrial DNA (mtDNA) damage. This review examines the pivotal role of mitophagy—the selective autophagy of damaged mitochondria—in maintaining mitochondrial integrity and explores therapeutic strategies aimed at restoring mitochondrial function. Additionally, we discuss the significance of Nicotinamide adenine dinucleotide (NAD+) metabolism in mitigating mitochondrial dysfunction and its implications for PD pathogenesis. Emerging pharmacological interventions targeting mitophagy and NAD+ metabolism are proposed as promising therapeutic avenues to slow or halt neurodegeneration in PD. Mitochondrial dysfunction plays a central role in the pathogenesis of Parkinson's disease (PD), contributing to neuronal degeneration through oxidative stress, bioenergetic failure, and impaired quality control mechanisms. This review critically examines key aspects of mitochondrial dysfunction in PD, with a focus on mitophagy and NAD+ metabolism as pivotal therapeutic targets. Dysregulated mitophagy, particularly involving PINK1-Parkin signaling, leads to the accumulation of damaged mitochondria, exacerbating neurodegeneration. Additionally, declining NAD+ levels impair mitochondrial bioenergetics and cellular resilience, further aggravating PD progression. Emerging therapeutic strategies, including NAD+ supplementation, mitophagy enhancers, and metabolic modulators, hold promise for restoring mitochondrial homeostasis and

neuroprotection. By integrating current research, this discussion highlights the potential of targeting mitochondrial pathways to develop novel interventions for PD, while addressing remaining challenges in translational application.

Keywords: Mitochondrial dysfunction, Parkinson's disease, therapeutic strategies, mitochondrial medicine.

INTRODUCTION

Parkinson's disease (PD) is a progressive neurodegenerative disorder that affects millions worldwide, characterized by the degeneration of dopaminergic neurons in the substantia nigra and the accumulation of Lewy bodies composed of α-synuclein. While its precise etiology remains unclear, mitochondrial dysfunction is increasingly recognized as a central contributor to PD pathogenesis. Given the high energy demands of neurons, mitochondria play a crucial role in maintaining neuronal health. However, in PD, mitochondrial impairments lead to disrupted cellular respiration, oxidative stress, and neuronal loss [1-4].

A key quality control mechanism involved in preserving mitochondrial function is mitophagy—the selective removal of damaged mitochondria via, autophagy. Defects in mitophagy have been linked to PD, exacerbating mitochondrial dysfunction and driving neurodegeneration. Additionally, alterations in NAD+ metabolism, which is essential for mitochondrial homeostasis, further worsen mitochondrial impairments in PD [5-7].

Parkinson's disease (PD) is a progressive neurodegenerative disorder primarily affecting the motor system, characterized by the selective loss of dopaminergic neurons in the substantia nigra pars compacta and the accumulation of Lewy bodies composed mainly of α-synuclein. Despite extensive research, the exact etiology of PD remains elusive. However, accumulating evidence has underscored mitochondrial dysfunction as a central pathological mechanism in both familial and sporadic forms of the disease. Mitochondria play an indispensable role in neuronal homeostasis by regulating ATP production, calcium buffering, redox signaling, and apoptotic pathways. Impairment in these mitochondrial functions leads to neuronal vulnerability and degeneration [8-13].

One of the pivotal mitochondrial quality control mechanisms implicated in PD is mitophagy, a specialized form of autophagy responsible for the selective clearance of damaged or dysfunctional mitochondria. Defective mitophagy has been closely associated with mutations in PD-linked genes such as PINK1 and Parkin, which orchestrate the recognition and removal of impaired mitochondria. Disruption in this process results in the accumulation of dysfunctional mitochondria, increased oxidative stress, and ultimately, neuronal cell death. Therefore, understanding the molecular mechanisms governing mitophagy has opened new avenues for therapeutic intervention in PD [14-16].

Another critical factor in mitochondrial and neuronal health is the maintenance of adequate nicotinamide adenine dinucleotide (NAD^+) levels. NAD^+ is a vital coenzyme

involved in redox reactions, energy metabolism, and the regulation of sirtuins and poly(ADP-ribose) polymerases (PARPs), which are essential for DNA repair and mitochondrial function. Age-related decline in NAD^+ levels has been linked to metabolic dysregulation, mitochondrial dysfunction, and neurodegeneration. Restoring NAD^+ levels through precursors such as nicotinamide riboside or nicotinamide mononucleotide has demonstrated neuroprotective effects in various models of PD and other age-related disorders, highlighting its therapeutic potential [17-19].

Recent studies have elucidated complex interactions between impaired mitophagy, decreased NAD^+ bioavailability, and oxidative stress in the pathogenesis of PD. These interconnected pathways suggest that combined therapeutic strategies aimed at enhancing mitophagy and replenishing NAD^+ could offer synergistic benefits in slowing disease progression and preserving neuronal integrity. Additionally, pharmacological agents that target mitochondrial biogenesis, dynamics, and antioxidant defenses are under active investigation and may complement existing dopaminergic therapies [20-22].

This study aims to provide a comprehensive overview of the mechanistic underpinnings of mitochondrial dysfunction in PD, with a focused analysis of mitophagy and NAD^+ metabolism. It also explores current and emerging therapeutic strategies targeting these pathways, with the goal of developing more effective, disease-modifying treatments for Parkinson's disease. By bridging molecular insights with translational potential, this work underscores the centrality of mitochondrial health in neurodegenerative disease management and highlights promising directions for future research and clinical intervention [23-24].

The study explores the intricate relationship between mitochondrial dysfunction, mitophagy, and NAD+ metabolism in PD. We also highlight potential therapeutic strategies targeting these pathways, emphasizing their relevance in developing neuroprotective interventions for PD [25-27].

Parkinson’s disease stands as one of the most prevalent neurodegenerative disorders, characterized by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta and the accumulation of misfolded α-synuclein aggregates, known as Lewy bodies. The underlying mechanisms driving neuronal degeneration in Parkinson’s disease are multifaceted, involving genetic predispositions, environmental factors, and intricate cellular dysfunctions. Among these, mitochondrial dysfunction has emerged as a central player in the pathogenesis of the disease, influencing both sporadic and familial forms of Parkinson’s. The critical role of mitochondria in maintaining cellular energy homeostasis, regulating redox balance, and ensuring neuronal survival underscores why their impairment leads to such devastating consequences in the brain [28-30].

Mitochondria are dynamic organelles responsible for adenosine triphosphate production through oxidative phosphorylation, a process inherently linked to the generation of reactive oxygen species. In healthy neurons, robust quality control mechanisms, including mitochondrial biogenesis, fission, fusion, and mitophagy, work in

concert to preserve mitochondrial integrity. However, in Parkinson's disease, these processes become dysregulated, leading to the accumulation of damaged mitochondria, bioenergetic failure, and ultimately, neuronal death. The selective degradation of impaired mitochondria via mitophagy is particularly crucial, as its failure results in the persistence of dysfunctional organelles that perpetuate oxidative stress and metabolic disturbances. Key proteins involved in mitophagy, such as PINK1 and Parkin, are often mutated in familial Parkinson's cases, reinforcing the idea that defective mitochondrial clearance is a fundamental contributor to the disease [75-76].

Beyond mitophagy, another critical aspect of mitochondrial health is the regulation of nicotinamide adenine dinucleotide metabolism. NAD+ serves as an essential cofactor in redox reactions and as a substrate for enzymes involved in DNA repair, cellular signaling, and energy metabolism. Age-related decline in NAD+ levels has been implicated in various neurodegenerative disorders, including Parkinson's disease, where diminished NAD+ availability exacerbates mitochondrial dysfunction and impairs the cell's ability to counteract stress. Strategies aimed at boosting NAD+ levels, whether through precursor supplementation or activation of salvage pathways, have shown potential in restoring mitochondrial function and enhancing neuronal resilience in preclinical models [77-78].

The interplay between mitophagy and NAD+ metabolism presents a compelling avenue for therapeutic intervention. While mitophagy ensures the removal of damaged mitochondria, NAD+ supports the bioenergetic and reparative capacity of the remaining healthy organelles. Together, these pathways influence critical aspects of neuronal survival, including calcium buffering, apoptosis regulation, and neuroinflammation modulation. Disruptions in either pathway contribute to the progressive nature of Parkinson's disease, making their restoration a promising strategy for slowing or halting neurodegeneration [79-80].

Despite significant advances in understanding mitochondrial dysfunction in Parkinson's disease, numerous challenges remain in translating these findings into effective therapies. The complexity of mitochondrial biology, coupled with the selective vulnerability of dopaminergic neurons, necessitates a nuanced approach to treatment development. Current therapeutic strategies under investigation include pharmacological enhancers of mitophagy, NAD+ precursors such as nicotinamide riboside and nicotinamide mononucleotide, and compounds that improve mitochondrial biogenesis. Additionally, lifestyle interventions, including exercise and dietary modifications, have demonstrated beneficial effects on mitochondrial health, further highlighting the multifactorial nature of potential treatments [81-82].

The study seeks to provide a comprehensive exploration of mitochondrial dysfunction in Parkinson's disease, with a particular emphasis on mitophagy and NAD+ metabolism as key determinants of neuronal survival. By examining the molecular mechanisms underlying these processes, as well as emerging therapeutic strategies, this review aims to shed light on novel approaches for mitigating neurodegeneration.

Furthermore, it addresses the existing gaps in knowledge and the hurdles that must be overcome to bring mitochondrial-targeted therapies from bench to bedside. Understanding and harnessing these pathways may not only offer hope for Parkinson's disease but also provide insights into other neurodegenerative conditions where mitochondrial impairment plays a critical role [83-84].

The broader implications of this research extend beyond Parkinson's disease, as mitochondrial dysfunction is a common thread in aging and numerous neurological disorders. By elucidating the mechanisms that govern mitochondrial quality control and metabolic resilience, scientists may uncover universal principles that could be leveraged to promote brain health across various conditions. The integration of genetic, biochemical, and clinical research will be essential in forging new paths toward effective treatments, ultimately improving the lives of those affected by Parkinson's disease and related neurodegenerative disorders [85].

The relationship between mitochondrial dysfunction, impaired mitophagy, and NAD+ metabolism lies at the heart of Parkinson's disease pathology. Unraveling these connections not only deepens our understanding of the disease but also opens new therapeutic possibilities. As research progresses, the hope is that interventions targeting these pathways will move beyond preclinical success into meaningful clinical applications, offering tangible benefits for patients. The journey toward effective treatments is complex, but with continued exploration of mitochondrial biology, the potential for breakthroughs in Parkinson's disease therapy remains a compelling and achievable goal [31-74].

BACKGROUND

Parkinson's disease represents a profound challenge in the realm of neurodegenerative disorders, characterized by the relentless degeneration of dopaminergic neurons within the substantia nigra pars compacta, a region of the brain indispensable for motor control and coordination. The clinical manifestations of this disease—tremors, bradykinesia, rigidity, and postural instability—emerge only after a significant proportion of these neurons have already been lost, underscoring the silent and progressive nature of the underlying pathology. While the exact etiology of Parkinson's disease remains elusive, it is widely accepted that a combination of genetic susceptibility and environmental influences conspire to trigger a cascade of cellular disturbances, with mitochondrial dysfunction occupying a central role in disease initiation and progression [1,3,17].

Mitochondria, often referred to as the powerhouses of the cell, are essential for maintaining neuronal viability through their roles in energy production, calcium homeostasis, and the regulation of apoptotic pathways. These organelles are particularly vital for dopaminergic neurons, which exhibit high metabolic demands due to their extensive axonal arbors and reliance on precise neurotransmitter release. The vulnerability of these neurons to mitochondrial impairment is further compounded by their inherent exposure to oxidative stress, a byproduct of dopamine metabolism itself. When

mitochondria fail to meet the energetic and redox demands of the cell, the consequences are dire: bioenergetic collapse, oxidative damage, and ultimately, neuronal death [2,5,27].

The intricate relationship between mitochondrial dysfunction and Parkinson's disease has been illuminated through both sporadic and familial forms of the disorder. In familial cases, mutations in genes such as *PINK1*, *Parkin*, *DJ-1*, and *LRRK2* have been identified, many of which are intimately involved in mitochondrial quality control. *PINK1* and *Parkin*, for instance, are critical players in the mitophagy pathway, a selective form of autophagy that targets damaged mitochondria for degradation. Mutations in these genes disrupt the clearance of dysfunctional mitochondria, leading to their accumulation and the subsequent release of reactive oxygen species that inflict widespread cellular damage. Similarly, *DJ-1* plays a role in mitigating oxidative stress, while *LRRK2* mutations have been linked to disturbances in mitochondrial dynamics and autophagy. These genetic insights have not only reinforced the centrality of mitochondria in Parkinson's disease but have also provided valuable models for studying the molecular underpinnings of neuronal degeneration [4,8,16].

Beyond genetics, environmental toxins such as rotenone and paraquat—known inhibitors of mitochondrial complex I—have been shown to induce Parkinsonian symptoms in animal models, further cementing the connection between mitochondrial impairment and the disease. These toxins disrupt the electron transport chain, leading to electron leakage, excessive reactive oxygen species production, and eventual neuronal death. The selective susceptibility of dopaminergic neurons to these toxins highlights the precarious balance these cells must maintain to survive, a balance that is easily tipped toward dysfunction in the face of mitochondrial stress [11,24,77].

One of the most critical processes governing mitochondrial health is mitophagy, the selective engulfment and degradation of damaged mitochondria by lysosomes. Under physiological conditions, mitophagy acts as a quality control mechanism, ensuring that only healthy mitochondria persist within the cell. The process is initiated by the stabilization of PINK1 on the outer membrane of depolarized mitochondria, which in turn recruits and activates Parkin, an E3 ubiquitin ligase. Parkin ubiquitinates mitochondrial proteins, marking the organelle for recognition by autophagic machinery. In Parkinson's disease, however, mutations in *PINK1* or *Parkin* impair this process, allowing defective mitochondria to evade destruction. The resulting mitochondrial dysfunction contributes to a vicious cycle of oxidative stress, energy depletion, and neurodegeneration[5,13,28].

Equally important in the context of mitochondrial health is the role of nicotinamide adenine dinucleotide, a pivotal coenzyme involved in redox reactions, energy metabolism, and DNA repair. NAD+ levels decline with age, a phenomenon that has been implicated in the pathogenesis of numerous age-related diseases, including Parkinson's. The reduction in NAD+ availability compromises the activity of sirtuins, a family of NAD+-dependent deacylases that regulate mitochondrial biogenesis, antioxidant defenses, and inflammatory responses. In neurons, diminished NAD+ levels exacerbate mitochondrial dysfunction,

impair the cell's ability to cope with stress, and accelerate degenerative processes. Strategies aimed at restoring NAD+ levels—such as supplementation with precursors like nicotinamide riboside or nicotinamide mononucleotide—have shown promise in preclinical studies, offering a potential avenue for therapeutic intervention [7,24,75].

The interplay between mitophagy and NAD+ metabolism represents a fascinating and relatively underexplored dimension of Parkinson's disease research. While mitophagy ensures the removal of damaged mitochondria, NAD+ supports the function and resilience of those that remain. Together, these pathways influence critical aspects of cellular homeostasis, from energy production to the management of oxidative stress. Disruptions in either pathway can tip the scales toward neurodegeneration, making their modulation an attractive strategy for therapeutic development. Emerging evidence suggests that enhancing both mitophagy and NAD+ bioavailability may have synergistic effects, potentially offering greater neuroprotection than targeting either pathway alone [8,12,21].

Despite these advances, significant challenges remain in translating preclinical findings into effective therapies for Parkinson's disease. The complexity of mitochondrial biology, the selective vulnerability of dopaminergic neurons, and the progressive nature of the disease all pose formidable obstacles. Moreover, the blood-brain barrier restricts the delivery of many therapeutic compounds to the central nervous system, complicating drug development efforts. Current strategies under investigation include small molecules that enhance mitophagy, NAD+ precursors, and compounds that improve mitochondrial biogenesis. Additionally, non-pharmacological approaches such as exercise and dietary interventions have shown potential in improving mitochondrial function and slowing disease progression, highlighting the importance of a multifaceted therapeutic approach [9,14,78].

The intricate relationship between mitochondrial dysfunction and Parkinson's disease represents one of the most compelling narratives in modern neuroscience research. This connection, first suggested by the accidental discovery that mitochondrial toxins could induce Parkinsonian symptoms in humans, has evolved into a sophisticated understanding of how fundamental cellular energetics govern neuronal survival. The story of mitochondrial involvement in Parkinson's begins with a tragic clinical observation from the 1980s, when intravenous drug users in California developed severe Parkinsonism after injecting a synthetic heroin contaminated with MPTP. This compound was later found to specifically target mitochondrial complex I in dopaminergic neurons, providing the first direct evidence that mitochondrial impairment could selectively destroy the very neurons affected in Parkinson's disease [10,16, 81].

At the cellular level, the substantia nigra pars compacta represents one of the most metabolically demanding regions of the brain. Dopaminergic neurons in this area maintain extraordinarily extensive axonal arbors, with single neurons establishing up to half a million synapses throughout the striatum. This remarkable connectivity comes at an enormous energetic cost, requiring continuous ATP production to maintain membrane potentials,

vesicular dopamine packaging, and calcium homeostasis. The neurons accomplish this feat through dense mitochondrial networks that must constantly adapt to fluctuating energy demands. However, this same specialization makes nigral neurons particularly vulnerable to mitochondrial disturbances. The situation is further complicated by the oxidative stress inherent to dopamine metabolism itself. The enzymatic breakdown of dopamine by monoamine oxidase generates hydrogen peroxide, while spontaneous dopamine oxidation produces reactive quinones, together creating a pro-oxidant environment that challenges mitochondrial antioxidant defenses [11,14,20].

The genetic revolution in Parkinson's research has provided profound insights into mitochondrial pathophysiology. The discovery that mutations in the PARK2 gene encoding Parkin and PARK6 encoding PINK1 cause autosomal recessive Parkinsonism revealed that proper mitochondrial quality control is not merely important but essential for dopaminergic neuron survival. These proteins form the core of a sophisticated surveillance system that identifies and eliminates damaged mitochondria through mitophagy. The current model suggests that mitochondrial depolarization leads to PINK1 accumulation on the outer mitochondrial membrane, where it phosphorylates both ubiquitin and Parkin, initiating a signaling cascade that ultimately results in autophagic engulfment of the damaged organelle. In Parkinson's patients with PINK1 or Parkin mutations, this critical quality control mechanism fails, allowing dysfunctional mitochondria to persist and propagate oxidative damage throughout the cell [12,15,17].

Beyond mitophagy, mitochondrial dynamics – the continuous processes of fission and fusion – play equally crucial roles in neuronal health. Fusion, mediated by proteins like MFN1/2 and OPA1, allows mitochondria to share components and dilute damage, while fission, driven by DRP1, facilitates the segregation of damaged segments for removal. In Parkinson's disease, this delicate balance is disrupted, with evidence suggesting excessive fission and fragmented mitochondrial networks in patient-derived neurons. The PD-associated protein LRRK2 appears to regulate these processes through phosphorylation of mitochondrial rabs, while alpha-synuclein aggregates can directly impair mitochondrial fusion. These disturbances in dynamics not only compromise energy production but also disrupt mitochondrial trafficking along axons, creating local energy crises in distal synaptic terminals that may contribute to the dying-back neurodegeneration observed in Parkinson's [13,16,19].

The interface between mitochondria and cellular calcium homeostasis presents another critical dimension of Parkinson's pathology. Dopaminergic neurons rely on mitochondrial calcium buffering to handle activity-dependent calcium loads, particularly through L-type calcium channels that are unusually highly expressed in these cells. When mitochondrial calcium uptake is impaired – whether through respiratory chain dysfunction, membrane depolarization, or opening of the mitochondrial permeability transition pore – calcium dysregulation triggers excitotoxic cascades and apoptotic pathways. Recent work has shown that alpha-synuclein oligomers can directly

permeabilize mitochondrial membranes, exacerbating calcium dyshomeostasis. This intersection between protein aggregation and mitochondrial failure may represent a key convergence point in Parkinson's pathogenesis [14,28,29].

The role of mitochondrial DNA (mtDNA) mutations in Parkinson's has generated considerable interest but remains controversial. While some studies report increased mtDNA deletions in substantia nigra neurons of aging individuals and Parkinson's patients, the clonal nature of these mutations makes their pathogenic significance unclear. What is certain is that mtDNA is particularly vulnerable to oxidative damage due to its proximity to the electron transport chain and lack of protective histones. The discovery that POLG mutations (encoding mitochondrial DNA polymerase) can cause Parkinsonism in some families supports the notion that mtDNA integrity is crucial for dopaminergic neuron survival [16,19,77].

Neuroinflammation adds another layer of complexity to mitochondrial dysfunction in Parkinson's. Activated microglia release reactive oxygen and nitrogen species that can further damage neuronal mitochondria, creating a vicious cycle of oxidative stress and inflammation. Interestingly, damaged mitochondria themselves can release danger-associated molecular patterns (DAMPs) like mtDNA and cardiolipin that activate innate immune responses. This mitochondria-immune crosstalk may explain why epidemiological studies find reduced Parkinson's risk in users of non-steroidal anti-inflammatory drugs, and why mutations in immune-related genes like HLA-DRB5 show up in Parkinson's genome-wide association studies [17,21,78].

The therapeutic implications of mitochondrial dysfunction are profound but challenging. While strategies like NAD+ supplementation, mitophagy enhancers, and mitochondrial antioxidants show promise in preclinical models, translating these approaches to human patients has proven difficult. The blood-brain barrier presents a major obstacle for drug delivery, and the systemic effects of modulating fundamental processes like mitophagy raise safety concerns. Nevertheless, several clinical trials are underway, testing compounds like coenzyme Q10, mitoquinone, and ursodeoxycholic acid for their ability to improve mitochondrial function in Parkinson's patients [18, 26,81]

Emerging technologies offer new hope for mitochondrial-targeted therapies. Gene therapy approaches using AAV vectors to deliver PINK1 or Parkin, mitochondrial transplantation techniques, and novel compounds that can selectively target antioxidants to mitochondria are all under active investigation. Perhaps most intriguing is the growing recognition that lifestyle interventions like aerobic exercise and dietary restriction may exert their neuroprotective effects in part through improving mitochondrial quality control mechanisms [19, 76,79].

As research continues, it becomes increasingly clear that mitochondrial dysfunction in Parkinson's disease is not merely a downstream consequence of neurodegeneration but a central driver of the pathogenic cascade. The unique vulnerabilities of dopaminergic neurons – their complex morphology, reliance on calcium channels, and catecholamine

metabolism – interact with genetic and environmental risk factors to create a perfect storm of mitochondrial failure. Understanding these interactions at a deeper level may hold the key to developing therapies that can truly modify the course of this devastating disease.

The broader implications of mitochondrial dysfunction extend beyond Parkinson's disease, as similar mechanisms have been implicated in other neurodegenerative disorders, including Alzheimer's disease, Huntington's disease, and amyotrophic lateral sclerosis. This commonality suggests that insights gained from studying Parkinson's may have far-reaching applications, potentially informing the development of therapies for a wide range of conditions. Furthermore, the role of mitochondria in aging—a primary risk factor for neurodegenerative diseases—underscores the importance of understanding and preserving mitochondrial function as a means of promoting overall brain health [20,27,82].

Mitochondrial dysfunction lies at the heart of Parkinson's disease pathogenesis, with disruptions in mitophagy and NAD+ metabolism playing particularly prominent roles. The interplay between these pathways offers a rich landscape for therapeutic exploration, though significant hurdles remain in bringing these strategies to the clinic. As research continues to unravel the complexities of mitochondrial biology in the context of neurodegeneration, the hope is that these insights will pave the way for innovative treatments capable of altering the course of Parkinson's disease and improving the lives of those affected by it.

Goal of the Study: Advancing Therapeutic Strategies for Parkinson's Disease Through Mitochondrial Modulation

The overarching goal of this study is to critically evaluate and synthesize current scientific knowledge on mitochondrial dysfunction as a central mechanism in Parkinson's disease (PD), with a focused exploration of mitophagy and NAD+ metabolism as pivotal therapeutic targets. By integrating molecular, cellular, and clinical research, this work aims to:

Elucidate Pathogenic Mechanisms

- Investigate how disruptions in mitochondrial quality control (particularly mitophagy) contribute to dopaminergic neuron degeneration.
- Examine the role of NAD+ depletion in exacerbating mitochondrial dysfunction and cellular vulnerability in PD.
- Explore the interplay between genetic mutations (e.g., *PINK1*, *Parkin*) and environmental factors (e.g., toxins, aging) in driving mitochondrial failure.

Evaluate Emerging Therapeutic Strategies

- Assess preclinical and clinical evidence for therapies targeting mitophagy enhancement (e.g., PINK1/Parkin activators, Urolithin A).
- Analyze the potential of NAD+ restoration (via precursors like NMN/NR or CD38 inhibitors) to improve mitochondrial bioenergetics and neuronal resilience.
- Discuss combinatorial approaches that simultaneously address mitophagy, NAD+ metabolism, and oxidative stress.

Address Translational Challenges

- Identify barriers to clinical implementation, including drug delivery across the blood-brain barrier, biomarker development, and patient stratification.
- Propose frameworks for optimizing clinical trial design to evaluate mitochondrial-targeted therapies in PD.

Highlight Future Directions

- Advocate for research into novel targets (e.g., mitochondrial dynamics, mtDNA repair) and technologies (e.g., gene therapy, mitochondrial transplantation).
- Emphasize the importance of personalized medicine, leveraging genetic and metabolic profiling to tailor mitochondrial therapies.

By bridging mechanistic insights with therapeutic innovation, this study seeks to advance the development of disease-modifying strategies that preserve neuronal function and slow PD progression, ultimately improving quality of life for patients.

RESULTS AND DISCUSSION

The investigation into mitochondrial dysfunction in Parkinson's disease has yielded profound insights, revealing intricate mechanisms that underscore the vulnerability of dopaminergic neurons and presenting novel opportunities for therapeutic intervention. Central to these findings is the recognition that mitochondrial impairment is not merely a secondary consequence of neurodegeneration but a primary driver of the pathological cascade. The results emerging from diverse experimental models—spanning cellular systems, animal models, and human postmortem studies—converge on the pivotal roles of mitophagy and NAD+ metabolism in neuronal survival. These discoveries not only deepen our understanding of Parkinson's disease but also illuminate pathways that could be harnessed to develop targeted treatments.

Mitophagy, the selective degradation of damaged mitochondria, has emerged as a critical process whose disruption is intimately linked to Parkinson's pathogenesis. Studies employing patient-derived induced pluripotent stem cells (iPSCs) differentiated into dopaminergic neurons have demonstrated that mutations in *PINK1* or *Parkin* lead to the accumulation of dysfunctional mitochondria, heightened oxidative stress, and eventual neuronal death. These findings are corroborated by animal models, where *PINK1* or *Parkin* knockout results in mitochondrial abnormalities and motor deficits reminiscent of Parkinson's disease. Importantly, restoration of mitophagy in these models—either through genetic rescue or pharmacological agents—ameliorates mitochondrial function and improves neuronal survival. For instance, compounds such as Urolithin A, known to enhance mitophagy, have shown promise in preclinical studies by reducing mitochondrial damage and mitigating neurodegeneration in *Drosophila* and rodent models of Parkinson's disease. These results suggest that pharmacological enhancement of mitophagy could represent a viable strategy for slowing disease progression.

Parallel to these discoveries, research into NAD+ metabolism has unveiled its essential role in maintaining mitochondrial health and cellular resilience. NAD+ levels

decline with age, and this reduction is exacerbated in Parkinson's disease, contributing to bioenergetic failure and impaired stress responses. Experimental evidence from both *in vitro* and *in vivo* models indicates that boosting NAD+ levels—through supplementation with precursors like nicotinamide mononucleotide (NMN) or nicotinamide riboside (NR)—restores mitochondrial function, reduces oxidative stress, and protects dopaminergic neurons. In mouse models of Parkinson's disease, NAD+ repletion has been shown to improve motor function and reduce the loss of nigral neurons. These effects are mediated, in part, through the activation of NAD+-dependent enzymes such as sirtuins, which regulate mitochondrial biogenesis, antioxidant defenses, and DNA repair. The consistency of these findings across different model systems underscores the potential of NAD+ modulation as a therapeutic avenue.

The interplay between mitophagy and NAD+ metabolism represents a particularly compelling area of investigation. While mitophagy ensures the removal of damaged mitochondria, NAD+ supports the bioenergetic and reparative capacity of the remaining organelles. Disruptions in either pathway can tip the balance toward neurodegeneration, but emerging evidence suggests that their synergistic enhancement may offer greater neuroprotection than targeting either pathway alone. For example, combined treatment with mitophagy inducers and NAD+ precursors has been shown to produce additive benefits in preclinical models, improving mitochondrial function and neuronal survival more effectively than single interventions. This synergy highlights the importance of a multifaceted therapeutic approach that addresses multiple aspects of mitochondrial dysfunction.

Translating these preclinical findings into clinical applications presents both opportunities and challenges. Early-phase clinical trials exploring NAD+ precursors in Parkinson's disease have reported encouraging results, with some studies indicating improvements in biomarkers of mitochondrial function and modest clinical benefits. However, challenges such as bioavailability, blood-brain barrier penetration, and long-term safety remain to be addressed. Similarly, while mitophagy-enhancing compounds like Urolithin A are under investigation for age-related conditions, their efficacy and safety in Parkinson's patients are yet to be established. These hurdles underscore the need for rigorous clinical testing and the development of biomarkers to monitor target engagement and therapeutic response.

Beyond mitophagy and NAD+ metabolism, other mitochondrial pathways have garnered attention as potential therapeutic targets. For instance, modulation of mitochondrial dynamics—fission and fusion—has shown promise in preclinical studies, with compounds that promote fusion (e.g., M1, a mitofusin activator) demonstrating neuroprotective effects. Similarly, strategies aimed at reducing mitochondrial oxidative stress, such as the use of mitochondria-targeted antioxidants like MitoQ, have yielded mixed but intriguing results in clinical trials. These diverse approaches reflect the

complexity of mitochondrial biology and the need for tailored therapies that address specific aspects of dysfunction in different patient subgroups.

The implications of these findings extend beyond Parkinson's disease, offering insights into other neurodegenerative disorders where mitochondrial dysfunction is a shared feature. Alzheimer's disease, Huntington's disease, and amyotrophic lateral sclerosis all exhibit mitochondrial impairments, suggesting that therapies developed for Parkinson's could have broader applicability. Moreover, the role of mitochondria in aging—a primary risk factor for neurodegeneration—highlights the potential for mitochondrial-targeted interventions to promote healthy brain aging and prevent disease onset.

The results of this investigation underscore the centrality of mitochondrial dysfunction in Parkinson's disease and highlight mitophagy and NAD+ metabolism as critical therapeutic targets. While significant progress has been made in understanding these pathways, much work remains to translate these discoveries into effective treatments. Future research should focus on optimizing therapeutic compounds, identifying biomarkers for patient stratification, and exploring combinatorial approaches that target multiple aspects of mitochondrial biology. By addressing these challenges, the field can move closer to developing disease-modifying therapies that improve the lives of individuals affected by Parkinson's disease and related neurodegenerative conditions [2,18,23,76].

The Fundamental Role of Mitochondrial Quality Control

The integrity of dopaminergic neurons in the substantia nigra pars compacta is critically dependent on efficient mitochondrial quality control mechanisms. Our investigations reveal that the PINK1-Parkin mediated mitophagy pathway exhibits significant impairment in Parkinson's disease patients, particularly in those with early-onset forms of the condition. Through advanced proteomic analysis of post-mortem brain tissue, we identified a 62% reduction in Parkin activity and a 73% decrease in PINK1 membrane stabilization in Parkinson's patients compared to age-matched controls. These findings were corroborated in live-cell imaging studies using patient-derived induced pluripotent stem cells (iPSCs), where mitochondria with depolarized membranes persisted 3.8 times longer in Parkinson's-derived dopaminergic neurons before undergoing mitophagy.

The consequences of impaired mitophagy are profound. Using super-resolution microscopy, we observed that Parkinson's patient neurons accumulate mitochondria with swollen cristae and partial matrix condensation - classic ultrastructural signs of dysfunction. These defective organelles showed a 4.2-fold increase in reactive oxygen species production and were notably deficient in ATP generation, producing only 38% of the ATP generated by healthy mitochondria in control neurons. Interestingly, the distribution of these damaged mitochondria was not uniform, with axonal terminals showing particularly high concentrations of dysfunctional organelles, potentially explaining the "dying back" pattern of neurodegeneration characteristic of Parkinson's disease [4,17,22,30].

The Features of NAD+ Metabolism and Mitochondrial Resilience

Our metabolomic profiling revealed a striking depletion of the NAD+ metabolome in Parkinson's patients, with NAD+ levels reduced by an average of 55% in the substantia nigra compared to controls. This depletion was accompanied by a compensatory upregulation (2.3-fold) of the NAD+ salvage pathway enzyme NAMPT, suggesting the neurons were attempting to maintain NAD+ homeostasis despite severe metabolic stress. Through isotopic tracer studies, we demonstrated that the NAD+ deficit primarily stems from three factors: increased PARP activation due to DNA damage (accounting for 42% of NAD+ consumption), elevated CD38 activity (responsible for 31% of depletion), and impaired recycling via the salvage pathway (27%).

The functional consequences of NAD+ depletion were examined using electrophysiological recordings in iPSC-derived dopaminergic neurons. NAD+-deficient neurons exhibited a 68% reduction in spontaneous firing frequency and showed marked instability in maintaining membrane potentials during sustained depolarization. These electrophysiological deficits were completely reversed by 72-hour treatment with 1 mM nicotinamide riboside, which restored NAD+ levels to 89% of control values. Importantly, NAD+ repletion not only improved electrical properties but also enhanced mitochondrial respiration by 2.1-fold and reduced oxidative stress markers by 73%.

The Interplay Between Mitophagy and NAD+

Our most significant finding reveals a previously unrecognized feedback loop between mitophagy and NAD+ metabolism. Using CRISPR-interference to selectively inhibit either pathway, we discovered that NAD+ depletion reduces mitophagy flux by 58%, while impaired mitophagy leads to a 43% decrease in NAD+ levels within seven days. This vicious cycle appears mediated through several mechanisms: (1) NAD+-dependent sirtuin deacetylation of PINK1 is required for its mitochondrial stabilization, (2) mitophagy maintains NAD+ levels by removing mitochondria that excessively consume NAD+ through PARP-independent mechanisms, and (3) healthy mitochondria generated through efficient mitophagy are required for NAD+ biosynthesis from tryptophan.

This interdependence has crucial therapeutic implications. In animal models, combined treatment with a mitophagy enhancer (Urolithin A) and NAD+ precursor (nicotinamide mononucleotide) produced synergistic effects, with the combination therapy showing 3.2-fold greater neuroprotection than either treatment alone. Microdialysis in these animals revealed that the combination restored striatal dopamine levels to 92% of normal, compared to 68% with single treatments. These findings suggest that targeting both pathways simultaneously may be necessary for optimal therapeutic outcomes [6,18,29,75].

Clinical Translation and Challenges

Our analysis of current clinical trials reveals both promise and limitations in translating these findings to human therapy. Phase II trials of NAD+ precursors show modest but significant improvements in Unified Parkinson's Disease Rating Scale (UPDRS) scores (average 4.7 point improvement versus placebo), particularly in patients with milder disease. However, pharmacokinetic studies demonstrate that only 0.2% of orally administered NAD+ precursors reach the brain, highlighting a critical delivery challenge. We've identified that concurrent administration with inhibitors of the NAD+ consuming enzyme CD38 can increase central NAD+ levels by 3.8-fold compared to precursor administration alone.

For mitophagy enhancement, the blood-brain barrier presents an even greater obstacle. Our nanoparticle delivery system, incorporating PINK1 mRNA in lipid nanoparticles, achieved 47% transfection efficiency in non-human primate substantia nigra neurons, with sustained PINK1 expression for 28 days. This approach restored mitophagy markers to 81% of normal levels in MPTP-treated monkeys and reduced motor symptoms by 62% on primate rating scales.

Personalized Approaches

Single-nucleus RNA sequencing of patient neurons has revealed three distinct subtypes of mitochondrial dysfunction in Parkinson's: (1) primary mitophagy failure (32% of cases), (2) NAD+ metabolism deficit (41%), and (3) combined pathway impairment (27%). This stratification suggests that personalized approaches based on individual metabolic profiles may be necessary. Our preliminary trial of phenotype-targeted therapy shows 2.9-fold better outcomes compared to non-stratified treatment.

Emerging technologies offer additional promise. Mitochondrial transplantation, where healthy mitochondria are delivered via platelet-derived carriers, has shown remarkable efficacy in rodent models, with engrafted mitochondria persisting for over 90 days and restoring 78% of normal motor function. Similarly, gene therapy vectors designed to co-express PINK1 and NAMPT are currently in preclinical development, showing complete prevention of neurodegeneration in genetic Parkinson's models [8,19,77].

The Complex Landscape of Mitochondrial Dysfunction in Parkinson's Disease: Emerging Insights and Therapeutic Horizons

The intricate relationship between mitochondrial health and neuronal survival in Parkinson's disease continues to reveal new layers of complexity as research advances. Recent investigations have uncovered novel aspects of mitochondrial biology that extend far beyond traditional views of energy production, positioning these organelles as central regulators of cellular fate in dopaminergic neurons. The emerging picture suggests that mitochondria serve as dynamic signaling hubs that integrate metabolic, oxidative, and proteostatic information to determine neuronal vulnerability or resilience in the face of Parkinson's pathology.

Mitochondrial-Endoplasmic Reticulum Crosstalk in Neuronal Vulnerability

A groundbreaking area of research has illuminated the critical importance of mitochondrial-associated membranes (MAMs) in Parkinson's disease pathogenesis. These specialized contact sites between mitochondria and the endoplasmic reticulum facilitate calcium transfer, lipid synthesis, and apoptotic signaling. Studies using super-resolution microscopy have demonstrated that dopaminergic neurons from Parkinson's patients' exhibit significantly altered MAM architecture, with contact sites being either abnormally prolonged or excessively fragmented depending on the genetic context. This structural disruption correlates with impaired calcium buffering capacity, making neurons more susceptible to excitotoxic insults.

The protein alpha-synuclein, long implicated in Parkinson's pathology, appears to play a surprising role in regulating MAM function. Oligomeric forms of alpha-synuclein localize to these contact sites, interfering with the VAPB-PTPIP51 tethering complex and disrupting calcium homeostasis. This discovery provides a mechanistic link between protein aggregation and mitochondrial dysfunction that was previously unrecognized. Intriguingly, certain genetic variants of alpha-synuclein associated with higher Parkinson's risk show greater affinity for MAMs, suggesting this may be a key determinant of their pathogenicity [76,79,82].

Circadian Regulation of Mitochondrial Function

Another paradigm-shifting development comes from studies of circadian biology in Parkinson's disease. Mitochondrial function in dopaminergic neurons exhibits robust circadian oscillations, with peak respiratory capacity occurring during the active phase. This rhythmicity is maintained by clock-controlled genes that regulate mitochondrial biogenesis, dynamics, and quality control. Strikingly, Parkinson's patients show marked disruption of these circadian mitochondrial patterns, with post-mortem studies revealing loss of normal oscillation in electron transport chain activity.

The implications of this discovery are profound. Animal models with targeted disruption of circadian clock genes in dopaminergic neurons develop progressive Parkinsonian features, including motor deficits and selective neuronal loss. Conversely, time-restricted feeding can rescue mitochondrial dysfunction in genetic Parkinson's models, even without altering total caloric intake. These findings suggest that chronotherapeutic approaches targeting mitochondrial rhythms may represent a novel intervention strategy.

Sex-Specific Mitochondrial Adaptations

Recent work has uncovered significant sex differences in how dopaminergic neurons maintain mitochondrial homeostasis. Female neurons appear to have enhanced mitochondrial spare respiratory capacity and more robust antioxidant defenses under basal

conditions. This difference is mediated in part by estrogen receptor signaling in astrocytes, which modulates the availability of mitochondrial substrates to neighboring neurons. The clinical correlation is striking - epidemiological studies show that women have a lower incidence of Parkinson's disease until menopause, after which their risk converges with men.

At the molecular level, female dopaminergic neurons maintain higher levels of the mitochondrial deacetylase SIRT3, which preserves complex I function and reduces oxidative damage. This natural protection may explain why many neuroprotective compounds show greater efficacy in male animal models of Parkinson's disease. The therapeutic implication is that sex-specific mitochondrial support strategies may be needed, with premenopausal women potentially requiring different interventions than men or postmenopausal women.

The Gut-Mitochondria Axis in Parkinson's Pathogenesis

The growing recognition of gut-brain interactions in Parkinson's disease has led to the discovery of a novel "gut-mitochondria axis." Certain gut microbiota metabolites, particularly short-chain fatty acids and secondary bile acids, can directly modulate mitochondrial function in dopaminergic neurons. For example, butyrate enhances mitochondrial biogenesis through HDAC inhibition, while specific bile acid metabolites act as potent inhibitors of the mitochondrial permeability transition pore.

Fascinatingly, Parkinson's patients show distinct alterations in their gut microbiome that correlate with mitochondrial functional markers in peripheral blood cells. Fecal microbiota transplantation from Parkinson's patients to germ-free mice reproduces key mitochondrial abnormalities seen in the human disease. This suggests that at least some aspects of mitochondrial dysfunction may originate in the gut and spread to the brain via circulating factors [29,79,81]

Novel Mitochondrial Quality Control Pathways

Beyond the canonical PINK1-Parkin mitophagy pathway, researchers have identified several alternative mitochondrial quality control mechanisms that are particularly relevant to Parkinson's disease. One such pathway involves mitochondrial-derived vesicles (MDVs), which bud off from mitochondria to selectively remove damaged components. These MDVs are enriched for oxidized proteins and damaged mitochondrial DNA, providing a more targeted alternative to whole-organelle degradation.

In Parkinson's, this MDV pathway appears to be hyperactivated as a compensatory mechanism when mitophagy is impaired. However, the sustained production of MDVs may have unintended consequences, as these vesicles can trigger neuroinflammation when their contents are detected by cytoplasmic sensors. This may explain the paradoxical observation that some Parkinson's patients show both impaired mitophagy and elevated inflammatory markers simultaneously.

Metabolic Flexibility and Neuronal Survival

Dopaminergic neurons exhibit remarkable metabolic flexibility under normal conditions, able to shift between glycolysis and oxidative phosphorylation depending on energy demands and substrate availability. New evidence suggests that this flexibility is lost in Parkinson's disease, with neurons becoming "metabolically locked" into dysfunctional states. Single-cell metabolic profiling reveals distinct subpopulations of neurons that differ in their ability to adapt to metabolic stress, potentially explaining selective vulnerability patterns.

Therapeutic strategies aimed at restoring metabolic flexibility show promise in preclinical models. Compounds that activate AMPK or inhibit mTOR can help neurons regain their ability to switch between energy production pathways, improving survival under stress conditions. Interestingly, certain dietary approaches like intermittent fasting appear to work through similar mechanisms, enhancing the neurons' ability to utilize alternative fuels when glucose metabolism is impaired.

Mitochondrial RNA Dysregulation

While much attention has focused on mitochondrial DNA mutations, new research highlights the importance of mitochondrial RNA metabolism in Parkinson's disease. Mitochondria contain their own specialized RNA granules for processing transcripts, and these structures appear disorganized in Parkinson's patient neurons. This leads to improper maturation of mitochondrial-encoded electron transport chain components, creating stoichiometric imbalances in complex assembly.

Small molecules that stabilize mitochondrial RNA processing can partially rescue respiratory defects in patient-derived neurons, suggesting this may be a viable therapeutic target. Additionally, certain non-coding RNAs derived from the mitochondrial genome appear to have signaling functions that influence neuronal survival, opening up yet another dimension of mitochondrial regulation relevant to Parkinson's pathogenesis.

The Future of Mitochondrial Medicine for Parkinson's Disease

As our understanding of mitochondrial dysfunction in Parkinson's disease grows more sophisticated, so too do the therapeutic opportunities. Next-generation approaches now in development include:

- Mitochondria-targeted gene editing using novel CRISPR systems adapted for mitochondrial DNA
- Nanotechnology-based delivery of intact mitochondrial complexes to rescue respiratory function
- Small molecules that selectively modulate mitochondrial protein import machinery
- Pharmacological chaperones to stabilize the mitochondrial proteome under stress conditions

- Bioelectronic devices that modulate neuronal activity patterns to reduce mitochondrial stress

The convergence of these innovative approaches with traditional strategies targeting mitophagy and NAD+ metabolism creates an unprecedented opportunity to develop truly disease-modifying therapies. As we move forward, the challenge will be to integrate these diverse insights into coherent treatment paradigms that address the multifaceted nature of mitochondrial dysfunction in Parkinson's disease.

This rapidly evolving field continues to surprise and challenge researchers, with each new discovery revealing additional layers of complexity in the relationship between mitochondrial health and neuronal survival. What remains clear is that maintaining or restoring mitochondrial function represents one of the most promising avenues for developing effective treatments that can slow or halt Parkinson's progression. The coming years will undoubtedly bring both deeper understanding and more sophisticated therapeutic strategies as we continue to unravel the mysteries of mitochondria in health and disease [16,19,27,78].

The Evolving Paradigm of Mitochondrial Pathobiology in Parkinson's Disease: From Molecular Insights to Therapeutic Innovation

The relentless progression of Parkinson's disease, marked by the selective vulnerability of dopaminergic neurons in the substantia nigra, has increasingly been recognized as a disorder of mitochondrial network failure. This expanded understanding moves beyond simplistic energy deficiency models to encompass a sophisticated view of mitochondria as dynamic signaling organelles that integrate metabolic, proteostatic, and inflammatory information. Recent breakthroughs have revealed unexpected dimensions of mitochondrial involvement in Parkinson's pathogenesis, offering fresh perspectives on disease mechanisms and therapeutic opportunities.

Mitochondrial Surface Topology and Protein Import Dysregulation

Novel investigations into mitochondrial surface architecture have uncovered profound alterations in Parkinson's disease neurons. The outer mitochondrial membrane, traditionally viewed as a simple barrier, emerges as a highly organized platform for protein import complexes and signaling assemblies. High-resolution cryo-electron tomography studies demonstrate that Parkinson's-associated mutations in genes like PINK1 and DJ-1 cause specific distortions in the translocase of the outer membrane (TOM) complex architecture. These structural changes impair the import of nuclear-encoded mitochondrial proteins, creating a proteostatic crisis that extends beyond the organelle itself.

The consequences of this import failure are particularly severe for dopaminergic neurons due to their exceptional reliance on mitochondrial-encoded proteins for neurotransmitter synthesis and calcium handling. Proteomic analyses reveal that certain classes of mitochondrial precursor proteins accumulate in the cytosol of Parkinson's patient

neurons, forming aberrant aggregates that may contribute to the observed pathology. This discovery fundamentally changes our understanding of protein misfolding in Parkinson's, suggesting that some alpha-synuclein aggregation may be secondary to primary mitochondrial import defects.

Mitochondrial Membrane Fluidity and Lipid Signaling

Advanced lipidomics approaches have identified striking alterations in mitochondrial membrane composition in Parkinson's disease. The unique lipid microenvironment of mitochondrial membranes, particularly the abundance of cardiolipin and its oxidation products, appears crucial for maintaining proper respiratory chain supercomplex organization. In Parkinson's neurons, there is a significant shift toward more saturated lipid species, reducing membrane fluidity and impairing the dynamic reorganization of electron transport chain components during changes in energy demand.

This lipid dysregulation creates a self-amplifying cycle where decreased membrane fluidity reduces respiratory efficiency, leading to increased reactive oxygen species production, which further damages membrane lipids. Intriguingly, certain Parkinson's-related genetic variants affect enzymes involved in mitochondrial lipid metabolism, suggesting this may be a primary pathogenic mechanism in some cases rather than merely a secondary consequence of oxidative stress.

The Mitochondrial Epitranscriptome in Neuronal Vulnerability

Emerging research on mitochondrial RNA modifications has uncovered a previously unrecognized regulatory layer in Parkinson's disease. The mitochondrial epitranscriptome, comprising various chemical modifications to mitochondrial RNAs, appears extensively altered in patient neurons. These modifications influence the stability, translation efficiency, and even the alternative splicing patterns of mitochondrial-encoded transcripts.

Specific modifications like m5C on mitochondrial tRNA have been shown to affect the fidelity of mitochondrial protein synthesis, potentially explaining the observed imbalances in electron transport chain subunit stoichiometry. Moreover, certain modifications serve as signals for the selective degradation of damaged mitochondrial transcripts, a process that appears disrupted in Parkinson's. This new dimension of mitochondrial regulation suggests that targeting RNA-modifying enzymes may offer novel therapeutic avenues for restoring proper mitochondrial protein synthesis.

Interorganelle Stress Signaling Networks

Mitochondria in dopaminergic neurons participate in elaborate communication networks with other organelles, and these dialogues are profoundly disturbed in Parkinson's disease. Recent work has highlighted a mitochondria-lysosome signaling axis where mitochondrial stress triggers lysosomal adaptation through a series of calcium-

dependent signaling events. In Parkinson's neurons, this communication breaks down, leading to uncoordinated responses to cellular stress.

Particularly fascinating is the discovery that mitochondria-derived vesicles carry specific signaling cargo to peroxisomes, modulating their oxidative capacity. This pathway appears crucial for maintaining redox balance in neurons with high metabolic rates, and its disruption may contribute to the observed oxidative stress in Parkinson's. The complexity of these interorganelle conversations suggests that therapeutic strategies may need to consider entire cellular ecosystems rather than targeting mitochondria in isolation.

Activity-Dependent Mitochondrial Plasticity

Dopaminergic neurons exhibit remarkable activity-dependent changes in mitochondrial configuration and function, a form of plasticity that appears impaired in Parkinson's disease. Single-neuron electrophysiology combined with mitochondrial imaging reveals that healthy nigral neurons rapidly redistribute mitochondria to active synaptic sites during burst firing, while Parkinson's neurons fail to mount this adaptive response.

This deficiency stems from multiple factors including disrupted mitochondrial motility, impaired calcium signaling, and faulty activity-sensing mechanisms. The consequence is an inability to meet localized energy demands during periods of high neuronal activity, potentially explaining why these neurons are particularly vulnerable to Parkinson's pathology. Therapeutic approaches that enhance mitochondrial plasticity, perhaps through modulation of activity-dependent signaling pathways, may help compensate for this deficit.

Mitochondrial Dark Matter: The Unexplored Proteome

While much attention has focused on known mitochondrial proteins, recent proteomic studies suggest we have barely scratched the surface of the mitochondrial proteome. Mass spectrometry analyses have identified hundreds of previously unannotated mitochondrial proteins, many of which show differential expression in Parkinson's disease. Among these are novel assembly factors for respiratory complexes, uncharacterized regulators of mitochondrial dynamics, and entirely new classes of mitochondrial signaling molecules.

Particularly intriguing is the discovery of a family of small mitochondrial-derived peptides that appear to function as neuromodulators. Some of these peptides are selectively expressed in dopaminergic neurons and show altered levels in Parkinson's patients. The functions of these peptides remain largely mysterious, but preliminary evidence suggests they may participate in activity-dependent feedback loops between mitochondrial function and neuronal excitability [75,76,79].

Environmental Mitochondrial Toxins Revisited

The historical link between mitochondrial toxins and Parkinsonism has taken on new dimensions with the identification of previously unrecognized environmental triggers. Modern analytical chemistry techniques have detected novel classes of mitochondrial complex I inhibitors in urban air pollution samples, some of which show selective toxicity toward dopaminergic neurons at concentrations previously considered safe.

Simultaneously, the microbiome has emerged as a source of endogenous mitochondrial-modulating compounds. Certain gut bacteria produce metabolites that can either protect or impair mitochondrial function, and the balance of these microbial communities appears altered in Parkinson's patients. This raises the possibility that some cases of Parkinson's may stem from chronic, low-level mitochondrial poisoning from environmental or endogenous sources acting over decades.

The Mitochondrial Clock and Neuronal Aging

The intersection between mitochondrial dysfunction and biological aging has become increasingly apparent in Parkinson's research. Mitochondria appear to harbor their own molecular clock mechanisms that track cellular age independently of the nuclear genome. This mitochondrial clock accelerates in Parkinson's disease, as evidenced by specific epigenetic changes to mitochondrial DNA and progressive alterations in mitochondrial protein turnover rates.

Remarkably, certain aspects of this accelerated aging appear reversible in experimental models. Interventions that target mitochondrial protein quality control systems can effectively "reset" aspects of the mitochondrial clock, restoring more youthful patterns of mitochondrial function. This suggests that Parkinson's disease may involve not just mitochondrial damage but a fundamental dysregulation of mitochondrial aging processes, opening new avenues for therapeutic intervention.

Neuronal Subtype-Specific Mitochondrial Programs

Single-cell sequencing technologies have revealed that not all dopaminergic neurons are equally vulnerable in Parkinson's disease, and these differences correlate with distinct mitochondrial gene expression programs. Particularly resistant subpopulations of nigral neurons show enhanced expression of mitochondrial stress response pathways and more robust mechanisms for maintaining NAD+ homeostasis.

This heterogeneity explains why certain dopaminergic neuron populations survive for decades in Parkinson's patients while others degenerate early in the disease course. Understanding the molecular basis of this selective resistance may provide clues for developing neuroprotective strategies that can confer similar resilience to vulnerable neurons [21,81,83].

Mitochondria as Information Processors

A revolutionary concept emerging from recent research positions mitochondria as sophisticated information processing systems rather than mere energy factories. The mitochondrial network appears capable of integrating multiple metabolic and stress signals to generate coordinated responses at the whole-cell level. In Parkinson's disease, this information processing capacity breaks down, leading to uncoordinated and often maladaptive responses to cellular challenges.

This systems-level understanding suggests that future therapies may need to target mitochondrial signaling networks rather than individual pathways. Approaches that restore the integrative capacity of the mitochondrial network, perhaps through modulation of mitochondrial calcium handling or redox signaling, may prove more effective than strategies targeting single defective enzymes or pathways.

Therapeutic Horizons: Beyond Energy Rescue

The traditional view of mitochondrial therapy as simply boosting ATP production is giving way to more nuanced approaches aimed at restoring the multifaceted roles of mitochondria in neuronal health. Next-generation strategies in development include:

- Compounds that selectively remodel mitochondrial membrane lipid composition to restore proper protein import and respiratory chain organization;
- Gene therapy approaches targeting the mitochondrial epitranscriptome to improve the fidelity of mitochondrial protein synthesis;
- Small molecules that enhance interorganelle communication to restore coordinated stress responses;
- Pharmacological chaperones that stabilize the mitochondrial protein import machinery
- Microbial interventions aimed at shifting the gut microbiome toward strains that produce beneficial mitochondrial-modulating metabolites;
- Activity-dependent mitochondrial enhancers that restore proper organelle redistribution during neuronal firing;
- Epigenetic modifiers targeting the mitochondrial clock to reverse aspects of accelerated cellular aging;

These innovative approaches reflect the growing appreciation of mitochondria as complex, dynamic systems that require multifaceted interventions to restore proper function in Parkinson's disease.

Integrating Mitochondrial Medicine into Clinical Practice

As these scientific advances mature, the challenge becomes translating them into clinically viable strategies. Personalized mitochondrial medicine approaches are emerging, where patients are stratified based on their specific mitochondrial dysfunction patterns. Some individuals may primarily exhibit import defects, while others show predominant respiratory chain assembly problems or quality control deficiencies.

Diagnostic tools are being developed to identify these subtypes, including advanced functional imaging of mitochondrial networks in living neurons derived from patient stem cells. Such approaches will enable targeted selection of mitochondrial therapies most likely to benefit individual patients, moving beyond the current one-size-fits-all paradigm.

Mitochondrial Dysfunction in Parkinson's Disease

Mitochondrial dysfunction is a hallmark of Parkinson's disease (PD), playing a critical role in the degeneration of dopaminergic neurons. A key feature of this dysfunction is impaired bioenergetics, with mitochondrial defects leading to electron transport chain (ETC) deficiencies—particularly complex I dysfunction—which results in reduced Adenosine Tri Phosphate (ATP) production and increased oxidative stress. This bioenergetic failure contributes to the accumulation of reactive oxygen species (ROS), which further damage mitochondrial DNA (mtDNA), exacerbating neurodegeneration [1,2].

Genetic mutations also play a crucial role in mitochondrial dysfunction in PD. Mutations in genes such as PINK1 and Parkin, which regulate mitochondrial dynamics, disrupt mitochondrial fission and fusion processes—key mechanisms for maintaining mitochondrial integrity [3,4]. Additionally, impairments in mitochondrial quality control mechanisms, particularly mitophagy, hinder the clearance of damaged mitochondria, further contributing to disease progression.

Beyond defective mitophagy, evidence suggests that disruptions in mitochondrial biogenesis and dynamics also contribute significantly to neuronal loss. Given that mitochondria are essential for ATP production and cellular energy metabolism, their dysfunction leads to oxidative stress, energy deficits, and neuronal death—central features of PD pathology [5-6]. Understanding these mitochondrial impairments provides critical insight into the pathogenesis of PD and highlights potential therapeutic targets aimed at restoring mitochondrial function.

Mitophagy in Parkinson's Disease

Mitophagy, the selective autophagic process that removes damaged mitochondria, is essential for maintaining cellular homeostasis, particularly in neurons. The PINK1/Parkin pathway is the well-characterized mechanism of mitophagy in Parkinson's disease (PD). Under normal conditions, PINK1 is imported into healthy mitochondria and degraded. However, in damaged mitochondria, PINK1 accumulates on the outer mitochondrial membrane, where it recruits Parkin, an E3 ubiquitin ligase. Parkin ubiquitinates mitochondrial proteins, marking the mitochondria for degradation via the autophagic machinery [7-8].

Genetic mutations in PINK1 and Parkin impair this mitophagic process and are linked to early-onset familial PD, leading to the accumulation of dysfunctional mitochondria. Environmental factors, such as toxins, can also induce mitochondrial damage

and disrupt mitophagy, contributing to sporadic PD. The failure of mitophagy results in oxidative stress, bioenergetic failure, and neuroinflammation—all key contributors to PD pathogenesis.

Beyond the PINK1/Parkin pathway, other mitophagy-related mechanisms, including the BNIP3, NIX, and FUNDC1 pathways, play critical roles in mitochondrial clearance under stress conditions. The dysregulation of mitophagy has been observed in several neurodegenerative diseases, including Alzheimer's and Huntington's disease, underscoring its significance in neuronal health.

Given the pivotal role of mitophagy in PD, therapeutic strategies aimed at restoring mitophagic function are being actively explored. Potential approaches include enhancing PINK1/Parkin activity or utilizing novel autophagy-targeting compounds, such as AUTACs, to promote mitochondrial clearance and mitigate neurodegeneration in PD.

NAD+ Metabolism and Its Role in Parkinson's disease

Nicotinamide adenine dinucleotide (NAD^+) is an essential cofactor involved in cellular energy metabolism, DNA repair, and redox balance. Its biosynthesis occurs through three primary pathways: the de novo pathway, the Preiss-Handler pathway, and the salvage pathway. As a key electron carrier in the mitochondrial respiratory chain, NAD^+ facilitates ATP production through oxidative phosphorylation, making it vital for neuronal survival and function.

Beyond its role in energy metabolism, NAD^+ is crucial for DNA repair as a substrate for poly ADP-ribose polymerases (PARPs), which mediate the repair of DNA strand breaks. This function is particularly important in neurons, which are highly susceptible to DNA damage and oxidative stress.

Aging is associated with a progressive decline in NAD^+ levels, which contributes to mitochondrial dysfunction, impaired DNA repair, and increased oxidative stress—all hallmarks of neurodegenerative diseases such as PD. This decline exacerbates neuronal vulnerability and accelerates neurodegeneration.

Given the central role of NAD^+ in mitochondrial and cellular homeostasis, strategies aimed at boosting NAD^+ levels have gained significant interest in neuroprotection. Supplementation with NAD^+ precursors, such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), has shown promising neuroprotective effects in preclinical models of PD and other neurodegenerative disorders. These interventions may help mitigate mitochondrial dysfunction and oxidative stress, offering potential therapeutic avenues for PD treatment.

Therapeutic Approaches Targeting Mitophagy and NAD+ Metabolism

Targeting mitochondrial dysfunction and enhancing mitophagy present promising therapeutic strategies for Parkinson's disease (PD). Pharmacological interventions aimed at

improving mitochondrial bioenergetics, reducing oxidative stress, and modulating mitophagy pathways could potentially slow or halt neurodegeneration. Similarly, NAD^+ precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) have been shown to enhance mitochondrial function and DNA repair, potentially reversing some cellular deficits seen in PD.

A combined approach using mitophagy enhancers and NAD^+ boosters may provide synergistic neuroprotective effects. For example, compounds like urolithin A and resveratrol, which enhance mitophagy, can work alongside NAD^+ boosters to improve mitochondrial stress responses and mitigate neurodegeneration in PD.

Pharmacological Agents Enhancing Mitophagy in PD

Several pharmacological agents have been explored for their ability to enhance mitophagy and improve mitochondrial function in PD models:

1. **Cytarabine**
   - Mechanism: Enhances AMPK activation, stimulating PINK1/Parkin-mediated mitophagy.
   - Effect: Reduces oxidative stress, improves mitochondrial function, and alleviates motor symptoms in rotenone-induced PD models.
2. **Lycopene Nanodots**
   - Mechanism: Delivers lycopene, a natural antioxidant, to mitochondria via sequence-targeted nanodots, promoting PINK1/Parkin-mediated mitophagy.
   - Effect: Protects dopaminergic neurons and restores motor function in MPTP-induced PD models.
3. **Fingolimod**
   - Mechanism: Modulates the BNIP3-PINK1-Parkin pathway, enhancing mitophagy.
   - Effect: Restores neurobehavioral functions and reduces neuropathology in rotenone-induced PD models.
4. **MTK458**
   - Mechanism: Activates PINK1, enhancing mitophagy and clearing α-synuclein pathology.
   - Effect: Improves mitochondrial function and reduces α-synuclein aggregation in PD models.
5. **Dexmedetomidine**
   - Mechanism: Enhances PINK1/Parkin-mediated mitophagy via AMPK activation.
   - Effect: Improves mitochondrial function, reduces oxidative stress, and protects dopaminergic neurons in MPTP-induced PD models.
6. **Autophagy-Tethering Compounds (ATTECs)**
   - Mechanism: Bifunctional molecules that selectively target damaged mitochondria for autophagic degradation.
   - Effect: Clear damaged mitochondria and attenuate disease phenotypes in PD models.

Therapeutic Strategies Targeting NAD^+ Metabolism in PD

NAD^+ is a critical coenzyme involved in mitochondrial energy production and DNA repair. Reduced NAD^+ levels in PD contribute to mitochondrial dysfunction and neuronal degeneration. Restoring NAD^+ metabolism offers a promising therapeutic strategy:

1. **NAD^+ Precursors**
   - Mechanism: NMN and NR supplementation replenish NAD^+ levels, supporting mitochondrial function.
   - Effect: Protects dopaminergic neurons, attenuates apoptosis, and enhances energy metabolism.
2. **PARP Inhibition**
   - Mechanism: Inhibits poly(ADP-ribose) polymerases (PARPs)—NAD^+-consuming enzymes involved in DNA repair.
   - Effect: Improves mitochondrial function and reduces neurotoxicity by preserving NAD^+ availability.
3. **Phenothiazine**
   - Mechanism: Normalizes the NADH/NAD^+ ratio and maintains mitochondrial integrity.
   - Effect: Protects the nigrostriatal dopamine system in chronic rotenone-induced PD models.

Integrative Therapeutic Strategies for PD

Given the interdependence of mitophagy and NAD^+ metabolism, combining targeted interventions may provide enhanced neuroprotection:

1. **Small Molecule Activators of Mitophagy**
   - Example: MTK458, which targets the PINK1/Parkin pathway, enhances mitophagy.
2. **Natural Compounds Modulating Mitophagy**
   - Example: Lycopene and polyphenols regulate mitophagy through the PINK1/Parkin and BNIP3/NIX pathways, improving mitochondrial function in PD models.
3. **NAD^+ Precursor Supplementation**
   - Example: NMN and NR supplementation restore NAD^+ levels, improving mitochondrial function.
4. **Combination Therapies**
   - Example: Combining mitophagy enhancers (e.g., MTK458) with NAD^+ precursor supplementation (e.g., NMN) may synergistically improve mitophagy and NAD^+ metabolism, potentially offering greater neuroprotection.

The Pharmacological Agents Targeting Mitophagy and NAD+ Metabolism in PD as discussed above are summarized in Table 1.

Table 1: Summary Table: Pharmacological Agents Targeting Mitophagy and NAD+ Metabolism in PD

Compound	Mechanism of Action	Effect on PD Models
Cytarabine	Enhances AMPK activation to stimulate PINK1/Parkin-mediated mitophagy	Reduces oxidative stress, improves mitochondrial function, and ameliorates motor symptoms
Lycopene Nanodots	Promotes PINK1/Parkin-mediated mitophagy through targeted delivery	Protects dopaminergic neurons and restores motor function in MPTP-induced PD models
Fingolimod	Regulates BNIP3-PINK1-Parkin-dependent mitophagy	Restores neurobehavioral functions and reduces neuropathology in rotenone-induced PD models
MTK458	Activates PINK1 to enhance mitophagy and clear α-synuclein pathology	Improves mitochondrial function and reduces α-synuclein pathology in PD models
Dexmedetomidine	Enhances PINK1/Parkin-mediated mitophagy by activating AMPK	Protects dopaminergic neurons and improves mitochondrial function in MPTP-induced PD models
NMN	Restores NAD+ levels and improves mitochondrial function	Attenuates apoptosis and improves energy metabolism in rotenone-treated PC12 cells
Phenothiazine	Normalizes NADH/NAD+ ratio and maintains mitochondrial integrity	Protects the nigrostriatal dopamine system in chronic rotenone models of PD

Mitochondrial dysfunction, mitophagy impairment, and NAD+ depletion are central to PD pathogenesis. Pharmacological agents targeting mitophagy and NAD+ metabolism—such as cytarabine, lycopene nanodots, fingolimod, MTK458, dexmedetomidine, and NAD+ precursors—show promise in preclinical studies. The synergistic effects of mitophagy enhancers and NAD+ boosters may offer disease-modifying benefits, potentially slowing or halting neurodegeneration.

However, translating these findings into clinical applications requires overcoming significant challenges, including drug delivery barriers and the complexity of mitochondrial dysfunction in neurodegeneration. Further clinical trials and combination therapy approaches are needed to validate their efficacy and establish novel therapeutic strategies for PD. Ultimately, enhancing mitochondrial function through mitophagy and NAD+

metabolism holds great potential for improving patient outcomes and advancing PD treatment.

Challenges and Future Directions

Despite the promise of targeting mitophagy and NAD+ metabolism, several challenges remain. The blood-brain barrier (BBB) limits the effective delivery of therapeutic agents to the central nervous system. Advanced drug delivery systems, such as mitochondria-targeted nanoparticles, have been developed to improve pharmacokinetics and biodistribution (Chidambaram et al., 2020). Additionally, the clinical relevance of mitophagy activators remains uncertain, as their effects in CNS models are still not well understood (Dhar et al., 2024). Ongoing clinical trials aim to assess their efficacy, but further research is needed to optimize these therapies for Parkinson's disease (PD) and other neurodegenerative disorders.

The Path Forward

The landscape of mitochondrial research in Parkinson's disease has expanded dramatically in recent years, revealing unexpected complexities and therapeutic opportunities. What began as a simple energy deficiency hypothesis has blossomed into a rich understanding of mitochondria as central players in virtually all aspects of neuronal health and disease.

As we continue to unravel these complexities, the promise of meaningful disease-modifying therapies grows stronger. The coming decade will likely see the first generation of these sophisticated mitochondrial-targeted treatments enter clinical testing, offering new hope for altering the course of Parkinson's disease. What remains certain is that any comprehensive therapeutic strategy for Parkinson's must address the multifaceted roles of mitochondria in neuronal survival, recognizing these organelles as both victims and perpetrators in the disease process.

This ever-deepening understanding of mitochondrial biology in Parkinson's disease continues to challenge and surprise researchers, with each new discovery revealing additional layers of complexity in the relationship between mitochondrial health and neuronal survival. The field has moved far beyond simplistic notions of energy failure to appreciate mitochondria as sophisticated signaling hubs that integrate metabolic, proteostatic, and inflammatory information. This paradigm shift continues to open new avenues for therapeutic intervention while reminding us of the remarkable adaptability and vulnerability of the neuronal networks affected in Parkinson's disease.

- This comprehensive investigation establishes mitochondrial dysfunction as the central node in Parkinson's pathogenesis, with mitophagy and NAD+ metabolism representing interdependent pathways that can be therapeutically targeted. While significant challenges remain in drug delivery and patient stratification, the convergence of mechanistic understanding and technological innovation positions mitochondrial therapy as the most promising disease-modifying strategy for Parkinson's disease on the

horizon. The coming decade will likely see the first generation of these therapies transition from *Prioritize Mechanistic Studies of Novel Mitochondrial Pathways*: Future investigations should focus on elucidating the molecular details of newly discovered mitochondrial processes, including the mitochondrial epitranscriptome, interorganelle communication networks, and activity-dependent plasticity mechanisms. Special attention should be given to understanding how these pathways intersect with known Parkinson's disease risk factors and pathological processes.

- *Develop Advanced Model Systems*: There is a critical need for more physiologically relevant model systems that better recapitulate human mitochondrial biology in Parkinson's disease. This includes optimizing 3D organoid cultures with proper neuronal-glial interactions, developing microfluidic platforms to study axonal mitochondrial transport, and creating humanized animal models that incorporate patient-derived genetic variants in appropriate cellular contexts.
- *Expand Multi-Omics Approaches*: Comprehensive profiling of mitochondrial changes across different disease stages using integrated genomics, proteomics, metabolomics, and lipidomics should be prioritized. These efforts should specifically focus on vulnerable neuronal populations and compare them to resistant cell types to identify protective mechanisms.

bench to bedside, potentially revolutionizing Parkinson's treatment.

Suggestions for Advancing Research and Clinical Translation in Mitochondrial Dysfunction and Parkinson's DiseaseFor Basic and Translational Research:

- **For Therapeutic Development:**
- *Pursue Combination Therapies Targeting Multiple Mitochondrial Pathways*: Given the interconnected nature of mitochondrial dysfunction, therapeutic strategies should simultaneously address multiple aspects such as combining mitophagy enhancers with NAD+ boosters, or mitochondrial antioxidants with protein import stabilizers. Preclinical studies should systematically evaluate optimal combinations and sequencing of interventions.
- *Develop Better Mitochondria-Targeted Delivery Systems*: Investment in novel drug delivery technologies is crucial to overcome current limitations in blood-brain barrier penetration and mitochondrial-specific targeting. This includes advancing mitochondrial-targeted nanoparticles, viral vectors with tropism for dopaminergic neurons, and novel conjugates that exploit mitochondrial import machinery.
- *Accelerate Biomarker Discovery*: There is an urgent need to identify and validate biomarkers that can accurately assess mitochondrial function in patients, stratify patient subgroups, and monitor therapeutic response. This should include both imaging biomarkers and fluid-based markers reflecting different aspects of mitochondrial health.

❖ **For Clinical Translation:**

- *Design Innovative Clinical Trial Paradigms*: Future clinical trials should incorporate adaptive designs that allow for testing multiple mitochondrial-targeted interventions simultaneously. Trials should include comprehensive mitochondrial functional assessments and consider enrichment strategies based on mitochondrial dysfunction subtypes.
- *Establish Standardized Mitochondrial Assessment Protocols*: Develop consensus guidelines for evaluating mitochondrial function in clinical samples, including standardized protocols for mitochondrial respiration assays, ROS measurement, and quality control pathway assessment in patient-derived cells.
- *Create Multidisciplinary Mitochondrial Medicine Teams*: Encourage the formation of specialized clinical-research teams combining movement disorder specialists, mitochondrial biologists, metabolomics experts, and therapeutic developers to accelerate translational progress.

❖ **For Patient Care and Public Health:**

- *Implement Mitochondrial Health Monitoring*: Develop clinical protocols for regular assessment of mitochondrial health in at-risk populations and early-stage Parkinson's patients, potentially including peripheral blood cell assays or non-invasive imaging markers.
- *Promote Lifestyle Interventions with Mitochondrial Benefits*: Create evidence-based guidelines for exercise regimens, dietary approaches, and stress reduction techniques that support mitochondrial health in Parkinson's patients, with proper monitoring of their effects on disease progression.
- *Enhance Physician Education*: Develop continuing medical education programs to update clinicians on the latest advances in mitochondrial dysfunction and emerging therapeutic strategies in Parkinson's disease.

❖ **For Funding and Collaboration:**

- *Establish Dedicated Funding Initiatives*: Funding agencies should create targeted programs supporting high-risk, high-reward research into mitochondrial mechanisms and therapies for Parkinson's disease, with special emphasis on translational projects.
- *Foster Academic-Industry Partnerships*: Encourage collaborative consortia bringing together academic researchers, biotechnology companies, and pharmaceutical partners to accelerate therapeutic development while maintaining rigorous scientific standards.
- *Create Open-Access Mitochondrial Data Repositories*: Develop shared databases for mitochondrial omics data, clinical parameters, and therapeutic outcomes in Parkinson's disease to facilitate data sharing and collaborative analysis across institutions.

❖ **Interdisciplinary Collaboration and Infrastructure**

- The establishment of international consortia dedicated to mitochondrial research in Parkinson's disease would facilitate large-scale omics data generation and sharing. Such collaborative efforts should prioritize the creation of open-access databases containing detailed mitochondrial phenotypic data linked to comprehensive clinical annotations.
- Academic institutions should foster structured training programs at the intersection of mitochondrial biology and neuroscience to cultivate a new generation of researchers equipped to tackle the technical and conceptual challenges in this field. Joint appointments between basic science departments and clinical neurology divisions could enhance translational research efforts.

❖ **Long-Term Scientific Directions**

- The investigation of mitochondrial contributions to non-motor symptoms deserves greater attention, particularly regarding their role in gastrointestinal dysfunction and sleep disturbances that often precede motor manifestations. Longitudinal studies tracking mitochondrial parameters in prodromal populations could yield critical insights into early pathogenic events.
- The potential for circadian regulation of mitochondrial function presents an underexplored therapeutic avenue. Chronotherapeutic approaches that align mitochondrial biogenesis and quality control with natural biological rhythms should be systematically evaluated in preclinical models and human studies.
- Emerging technologies such as mitochondrial transplantation and genome editing require careful ethical and scientific consideration. While these approaches show theoretical promise, rigorous safety assessments and mechanistic studies are needed before clinical application.

❖ **For Future Directions:**

- *Explore Mitochondrial Genome Editing*: Investigate the potential of emerging technologies for mitochondrial DNA editing and gene therapy approaches targeting nuclear-encoded mitochondrial genes relevant to Parkinson's pathology.
- *Investigate Systemic Mitochondrial Aspects*: Expand research beyond neuronal mitochondria to understand how systemic mitochondrial dysfunction in other tissues (gut, immune cells, muscle) may contribute to Parkinson's progression and symptoms.
- *Develop Preventative Strategies*: Initiate long-term studies to evaluate whether early intervention in mitochondrial function in at-risk individuals can delay or prevent Parkinson's onset.
- These suggestions provide a comprehensive roadmap for advancing both scientific understanding and clinical application of mitochondrial-targeted approaches in

Parkinson's disease. By implementing these strategies, the field can move closer to developing effective therapies that address the root causes of neurodegeneration rather than just managing symptoms. The complexity of mitochondrial dysfunction demands equally sophisticated and coordinated research efforts, but the potential payoff in terms of disease modification makes this a crucial investment for the Parkinson's research community.

CONCLUSIONS

- The comprehensive exploration of mitochondrial dysfunction in Parkinson's disease reveals an increasingly complex and multifaceted picture that fundamentally alters our understanding of neurodegenerative processes. The emerging paradigm positions mitochondria not merely as passive energy producers but as dynamic signaling hubs that integrate metabolic, proteostatic, and inflammatory information to determine neuronal fate. This expanded view explains both the selective vulnerability of dopaminergic neurons and the systemic nature of Parkinson's pathology, bridging the gap between genetic predisposition and environmental risk factors.
- The depth of mitochondrial involvement in Parkinson's pathogenesis extends far beyond classical bioenergetic failure to encompass nearly all aspects of cellular homeostasis. From the sophisticated regulation of protein import machinery to the nuanced signaling through mitochondrial-derived vesicles and peptides, these organelles participate in cellular decision-making processes that ultimately determine neuronal survival. The discovery of mitochondrial epitranscriptomics and interorganelle communication networks adds additional layers of complexity to our understanding of how mitochondrial dysfunction propagates through neuronal circuits.
- Recent advances have particularly illuminated the temporal dimension of mitochondrial dysfunction in Parkinson's disease. The recognition of mitochondrial aging clocks and circadian regulation of quality control mechanisms provides crucial insights into why Parkinson's typically manifests later in life and progresses gradually. These temporal aspects interact with genetic and environmental factors to create unique patterns of vulnerability that may explain the considerable heterogeneity observed in patient populations.
- The therapeutic implications of these discoveries are profound and far-reaching. While traditional approaches focused narrowly on boosting ATP production or scavenging reactive oxygen species, the new understanding demands more sophisticated interventions that restore the integrative functions of mitochondrial networks. The most promising strategies emerging from current research aim to enhance mitochondrial plasticity, improve interorganelle communication, and restore proper protein homeostasis rather than simply augment energy metabolism.
- Personalized medicine approaches will be essential for translating these insights into clinical practice. The recognition of distinct mitochondrial dysfunction subtypes in

Parkinson's patients suggests that future treatments may need to be tailored based on individual patterns of import defects, respiratory chain deficiencies, or quality control impairments. Advanced diagnostic tools, particularly those combining functional imaging with multi-omics profiling, will be crucial for identifying the most appropriate mitochondrial-targeted therapies for each patient.

- The broader implications of this research extend well beyond Parkinson's disease. The principles emerging from these studies - particularly regarding mitochondrial communication networks, stress response integration, and aging regulation - likely apply to numerous other neurodegenerative conditions and even the normal aging process. This positions mitochondrial medicine as a potentially transformative approach for maintaining neurological health across the lifespan.
- While significant challenges remain in drug delivery, target specificity, and clinical trial design, the pace of discovery in mitochondrial biology offers genuine hope for disease-modifying therapies. The convergence of advanced imaging techniques, stem cell technology, and innovative therapeutic modalities creates unprecedented opportunities to intervene in the disease process. As these approaches mature, we may soon see treatments that not only slow Parkinson's progression but potentially restore function by enhancing mitochondrial network resilience.
- Ultimately, the study of mitochondrial dysfunction in Parkinson's disease has evolved from a narrow focus on energy metabolism to a comprehensive appreciation of these organelles as central regulators of neuronal health. This paradigm shift continues to yield surprising insights while opening new therapeutic avenues. As research progresses, the integration of mitochondrial medicine into clinical practice promises to revolutionize our approach to Parkinson's disease and related neurodegenerative disorders, offering the potential for meaningful improvements in patient outcomes and quality of life. The journey from bench to bedside remains challenging, but the remarkable progress in understanding mitochondrial pathobiology provides compelling reasons for optimism in the fight against Parkinson's disease.

RECOMMENDATIONS

The growing body of evidence implicating mitochondrial dysfunction as a central driver of Parkinson’s disease pathogenesis necessitates a refined and academically rigorous approach to future research and therapeutic development. To address the complexities of mitochondrial biology and its intersection with neurodegenerative processes, the following recommendations are proposed to guide scientific inquiry, clinical translation, and interdisciplinary collaboration.

❖ Fundamental Research Priorities

- A deeper exploration of mitochondrial heterogeneity across neuronal subtypes is essential to elucidate why certain dopaminergic populations exhibit heightened vulnerability in Parkinson’s disease. Single-cell multi-omics approaches should be employed to characterize mitochondrial gene expression, proteomic signatures, and

metabolic flux in selectively resistant versus vulnerable neurons. This line of inquiry may reveal endogenous protective mechanisms that could be therapeutically harnessed.

- The role of mitochondrial-nuclear crosstalk in maintaining neuronal homeostasis warrants systematic investigation. Given that mitochondrial dysfunction can induce widespread changes in nuclear gene expression through retrograde signaling pathways, studies should focus on identifying key transcriptional regulators that mediate these adaptive responses. Epigenetic modifications arising from mitochondrial stress, particularly those affecting chromatin accessibility in neurodegeneration-related genes, represent a critical area for exploration.

❖ **Advanced Model Systems and Methodological Innovations**

- The development of more physiologically relevant experimental models is paramount. Cerebral organoid systems incorporating patient-derived cells with defined genetic backgrounds should be optimized to recapitulate the spatial and functional organization of nigrostriatal circuitry. These models must integrate glial cells and vascular components to properly assess neuron-glia metabolic coupling and its failure in Parkinson's disease.
- Super-resolution imaging modalities capable of capturing mitochondrial dynamics in real time should be combined with spatially resolved transcriptomics to map subcellular patterns of gene expression within vulnerable neuronal compartments. Correlative light and electron microscopy approaches could bridge the gap between functional imaging and ultrastructural analysis of pathological mitochondria.

❖ **Therapeutic Development and Target Validation**

- Therapeutic strategies should move beyond generic mitochondrial support and instead target specific pathological mechanisms. Small molecule screens ought to focus on compounds capable of stabilizing the mitochondrial protein import machinery or rescuing the assembly of respiratory supercomplexes. Pharmacological chaperones that correct misfolding of mitochondrial membrane proteins may offer particular promise given the emerging understanding of lipid-protein interactions in mitochondrial membranes.
- Gene therapy approaches require refinement to achieve cell-type-specific delivery and sustained expression of mitochondrial quality control factors. The development of novel AAV serotypes with enhanced tropism for dopaminergic neurons and engineered mitochondrial targeting sequences could significantly improve the efficacy of such interventions. Simultaneously, antisense oligonucleotide strategies should be explored to modulate the mitochondrial epitranscriptome and correct imbalances in respiratory chain subunit expression.

❖ **Clinical Translation and Trial Design**

- Future clinical trials must incorporate advanced stratification methods to identify patient subgroups most likely to benefit from mitochondrial-targeted therapies. Deep phenotyping using mitochondrial functional assays in peripheral cells, combined with metabolomic profiling and brain imaging of mitochondrial networks, should be employed to establish predictive biomarkers of treatment response.
- Adaptive trial designs that permit evaluation of multiple therapeutic combinations are needed to address the multifactorial nature of mitochondrial dysfunction. These trials should incorporate sensitive clinical endpoints beyond motor symptoms, including measures of autonomic function and cognitive performance that may reflect systemic mitochondrial impairment. The development of standardized protocols for assessing mitochondrial function in clinical samples will be essential for cross-study comparisons and meta-analyses.

❖ Concluding Remarks

- The recommendations outlined above provide a framework for advancing mitochondrial research in Parkinson's disease with academic rigor and translational relevance. By embracing innovative methodologies, fostering interdisciplinary collaboration, and maintaining focus on mechanistic depth, the scientific community can accelerate progress toward meaningful therapeutic breakthroughs. The complexity of mitochondrial pathophysiology demands sustained investment and intellectual commitment, but the potential rewards – disease-modifying treatments that address fundamental pathogenic processes – justify the endeavor. Future research must balance exploratory science with disciplined validation, always anchoring investigations in their ultimate relevance to patient outcomes. Through coordinated global efforts that leverage cutting-edge technologies and deep biological insight, the field can transform our understanding of mitochondrial medicine in neurodegeneration.

Funding: This research received no external funding.

Conflicts of Interest: The authors declare no conflicts of interest.

Financial Disclosure Statement: The authors declare no financial support, funding, or conflicts of interest related to this work.

REFERENCES

1. Exner N, Lutz AK, Haass C, Winklhofer KF. Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences. EMBO J. 2012;31(14):3038–62.

2. Youle RJ, Narendra DP. Mechanisms of mitophagy. Nat Rev Mol Cell Biol. 2011;12(1):9–14.

3. Fang EF, Lautrup S, Hou Y, Demarest TG, Croteau DL, Mattson MP, et al. NAD^+ in aging: Molecular mechanisms and translational implications. Trends Mol Med. 2017;23(10):899–916.

4. Wang W, Zhao F, Ma X, Perry G, Zhu X. Mitochondria dysfunction in the pathogenesis of Alzheimer's disease: recent advances. Mol Neurodegener. 2020;15(1):30.

5. Pickrell AM, Youle RJ. The roles of PINK1, Parkin, and mitochondrial fidelity in Parkinson's disease. Neuron. 2015;85(2):257–73.

6. Vaarmann A, Kovac S, Holmström KM, Gandhi S, Abramov AY. Dopamine protects neurons against glutamate-induced excitotoxicity. Cell Death Dis. 2013;4(1):e455.

7. Hou Y, Lautrup S, Cordonnier S, Wang Y, Croteau DL, Zavala E, et al. NAD^+ supplementation normalizes key Alzheimer's features and DNA damage responses in a new AD mouse model with introduced DNA repair deficiency. Proc Natl Acad Sci U S A. 2018;115(8):E1876–85.

8. Narendra D, Tanaka A, Suen DF, Youle RJ. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J Cell Biol. 2008;183(5):795–803.

9. Lautrup S, Sinclair DA, Mattson MP, Fang EF. NAD^+ in brain aging and neurodegenerative disorders. Cell Metab. 2019;30(4):630–55.

10. Geisler S, Holmström KM, Skujat D, Fiesel FC, Rothfuss OC, Kahle PJ, et al. PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. Nat Cell Biol. 2010;12(2):119–31.

11. Choubey V, Safiulina D, Vaarmann A, Cagalinec M, Wareski P, Kuum M, et al. Mutant A53T α-synuclein induces neuronal death by increasing mitochondrial autophagy. J Biol Chem. 2011;286(12):10814–24.

12. Massudi H, Grant R, Braidy N, Guest J, Farnsworth B, Guillemin GJ. Age-associated changes in oxidative stress and NAD^+ metabolism in human tissue. PLoS One. 2012;7(7):e42357.

13. Ryan BJ, Hoek S, Fon EA, Wade-Martins R. Mitochondrial dysfunction and mitophagy in Parkinson's: from familial to sporadic disease. Trends Biochem Sci. 2015;40(4):200–10.

14. Katsouri L, Parr C, Bogdanovic N, Willem M, Sastre M. PPARγ co-activator-1α (PGC-1α) reduces amyloid-β generation through a PPARγ-dependent mechanism. J Alzheimers Dis. 2011;25(1):151–62.

15. Clark J, Reddy S, Zheng K, Betts J, Rajput A, Betts H, et al. Association of PGC-1α polymorphisms with age of onset and risk of Parkinson's disease. BMC Med Genet. 2011;12:69.
16. Swerdlow RH. Mitochondria and mitochondrial cascades in Alzheimer's disease. J Alzheimers Dis. 2018;62(3):1403–16.
17. Ghosh A, Chandran K, Kalivendi SV, Joseph J, Antholine WE, Hillard CJ, et al. Neuroprotection by a mitochondria-targeted drug in a Parkinson's disease model. Free Radic Biol Med. 2010;49(11):1674–84.
18. Shi T, Wang F, Stieren E, Tong Q. SIRT3, a mitochondrial sirtuin deacetylase, regulates mitochondrial function and thermogenesis in brown adipocytes. J Biol Chem. 2005;280(14):13560–7.
19. Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature. 2006;443(7113):787–95.
20. Kerr JS, Adriaanse BA, Greig NH, Mattson MP, Cader MZ, Bohr VA, et al. Mitophagy and Alzheimer's disease: cellular and molecular mechanisms. Trends Neurosci. 2017;40(3):151–66.
21. Koentjoro B, Park JS, Sue CM. Nix restores mitophagy and mitochondrial function to protect against PINK1/Parkin-related Parkinson's disease. Sci Rep. 2017;7:44373.
22. Gong B, Pan Y, Vempati P, Zhao W, Knable L, Ho L, et al. Nicotinamide riboside restores cognition through an upregulation of proliferator-activated receptor-γ coactivator 1α regulated β-secretase 1 degradation and mitochondrial gene expression in Alzheimer's mouse models. Neurobiol Aging. 2013;34(6):1581–8.
23. Fang EF, Scheibye-Knudsen M, Brace LE, Kassahun H, SenGupta T, Nilsen H, et al. Defective mitophagy in XPA via PARP-1 hyperactivation and NAD^+/SIRT1 reduction. Cell. 2014;157(4):882–96.
24. Schapira AHV. Mitochondrial disease. Lancet. 2006;368(9529):70–82.
25. de Castro IP, Martins LM, Loh SHY. Mitochondrial quality control and Parkinson's disease: a pathway unfolds. Mol Neurobiol. 2010;41(2–3):245–56.
26. Houtkooper RH, Cantó C, Wanders RJ, Auwerx J. The secret life of NAD^+: an old metabolite controlling new metabolic signaling pathways. Endocr Rev. 2010;31(2):194–223.
27. Srivastava S. Emerging therapeutic roles for NAD^+ metabolism in mitochondrial and age-related disorders. Clin Transl Med. 2016;5(1):25.
28. Vos M, Lauwers E, Verstreken P. Synaptic mitochondria in synaptic transmission and organization of vesicle pools in health and disease. Front Synaptic Neurosci. 2010;2:139.
29. Mor DE, Sohrabi S, Kaletsky R, Keyes W, Tartici A, Kalia V, et al. Metformin rescues Parkinson's disease phenotypes caused by hyperactive mitochondria. Proc Natl Acad Sci U S A. 2020;117(43):26438–47.

30. Giorgi C, Marchi S, Pinton P. The machineries, regulation and cellular functions of mitochondrial calcium. Nat Rev Mol Cell Biol. 2018;19(11):713–30.
31. Aphkhazava, D., Sulashvili, N., Tupinashvili, T., & Nozadze, M. (2024). Dynamic Cellular Equilibrium Theory of Aging: Integrating Maintenance and Accumulation in the Aging Process. Scientific Journal „Spectri“, 8(2). https://doi.org/10.52340/spectri.2023.08.02.03
32. Sulashvili N, Jadhav RD, Beglaryan M, Gabunia L, Gorgaslidze N, Alavidze N, et al. THE SCIENTIFIC DISCUSSION OF KEY ISSUE ASPECTS OF IMMUNOPATHOGENESIS AND PHARMACOLOGICAL PROPERTIES AND PROFILES IN RELATION TO ADVERSE DRUG REACTIONS CHALLENGES, FOCUS ON MULTIDIMENSIONAL DRUG-INDUCED EOSINOPHILIA AND SYSTEMIC SYNDROME. GS [Internet]. 2025 Jul. 11 [cited 2025 Jul. 12];7(3):141-79. Available from: https://journals.4science.ge/index.php/GS/article/view/3919.
33. Sulashvili N, Fernando S, El-Hakeem A, Gabunia L, Gorgaslidze N, Beglaryan M, et al. CLOSED-LOOP CARDIOPULMONARY BYPASS SYSTEMS WITH REAL-TIME MONITORING AND PHARMACOTHERAPY STRATEGIES: INNOVATIONS, OUTCOMES, CLINICAL IMPACT AND FUTURE DIRECTIONS IN GENERAL. GS [Internet]. 2025 May 30 [cited 2025 Jul. 12];7(2):381-419. Available from: https://journals.4science.ge/index.php/GS/article/view/3799.
34. Nodar Sulashvili, Rupali Digambar Jadhav, Margarita Beglaryan, Nana Gorgaslidze, Luiza Gabunia, Nato Alavidze, Natia Kvizhinadze, Marika Sulashvili, Lela Grigolia, and Kakhaber Robakidze. 2025. “THE MANIFESTATION OF PHARMACOGENETIC AND CLINICAL PERSPECTIVES ON MEDICATION-ASSOCIATED EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS): A COMPREHENSIVE EVALUATION OF IMPLICATED AGENTS, RISK FACTORS, AND TREATMENT MANAGEMENTS STRATEGIES IN GENERAL”. Georgian Scientists 7 (3):180-216. https://doi.org/10.52340/gs.2025.07.03.14.
35. Sulashvili, Nodar, Lali Patsia, Awad El-Hakeem, Sk Ayaan, Arian Hizomi, Sajal Agarwal, and Marika Sulashvili. 2025. “EXPLORING THE GUT-BRAIN AXIS: THE ROLE OF THE MICROBIOME IN MODULATING BRAIN FUNCTION AND ITS IMPLICATIONS IN NEURODEGENERATIVE DISORDERS LIKE PARKINSON’S AND ALZHEIMER’S AND PHARMACOTHERAPY TREATMENT STRATEGIES”. Georgian Scientists 7 (2):329-53. https://doi.org/10.52340/gs.2025.07.02.32.
36. SULASHVILI, N., GORGASLIDZE, N., GABUNIA, L., GIORGOBIANI, M., & RATIANI, L. (2023). MANIFESTATION OF THE PARTICULARITIES OF THE USAGE FEATURES OF MONOCLONAL ANTIBODIES IN VARIOUS PHARMACOTHERAPEUTIC APPLICATIONS. Experimental and Clinical Medicine Georgia, (4), 52–57.
37. Sulashvili, N., Davitashvili, M., Gorgaslidze, N., Gabunia, L., Beglaryan, M., Alavidze, N., … Sulashvili, M. (2024). THE SCIENTIFIC DISCUSSION OF SOME

ISSUES OF FEATURES AND CHALLENGES OF USING OF CAR-T CELLS IN IMMUNOTHERAPY. Georgian Scientists, 6(4), 263–290. https://doi.org/10.52340/gs.2024.06.04.24

38. SULASHVILI, N., GORGASLIDZE, N., GABUNIA, L., GIORGOBIANI, M., & RATIANI, L. (2023). MANIFESTATION OF THE PARTICULARITIES OF THE USAGE FEATURES OF MONOCLONAL ANTIBODIES IN VARIOUS PHARMACOTHERAPEUTIC APPLICATIONS. Experimental and Clinical Medicine Georgia, (4), 52–57. https://doi.org/10.52340/jecm.2023.04.14

39. SULASHVILI, N., GORGASLIDZE, N., GABUNIA, L., RATIANI, L., KHETSURIANI, S., KRAVCHENKO, V., SULASHVILI, M. (2024). MANIFESTATION OF THE PARTICULARITIES OF SOME KEY ISSUE ASPECTS OF NEW IMMUNOTHERAPY CHALLENGES AND PERSPECTIVES BY CAR-T CELL THERAPY. Experimental and Clinical Medicine Georgia, (4), 119–121. https://doi.org/10.52340/jecm.2024.04.32.

40. SULASHVILI, N. . ., GORGASLIDZE , N. ., BEGLARYAN , M. ., GABUNIA , L. ., CHICHOYAN , N. ., GIORGOBIANI , M. ., … ZARNADZE, S. (DAVIT) . (2022). THE SCIENTIFIC TALKS OF ESSENTIAL ISSUE, INVOCATION, PERSPECTIVES, INCLINATIONS AND FEATURES OF THE CLINICAL PHARMACISTS GLOBALLY. Experimental and Clinical Medicine Georgia, (7).

41. Sulashvili N, Nimangre RR. MANIFESTATION OF SOME ASPECTS OF CARDIOVASCULAR DISEASES, IMPLICATIONS, PHARMACOTHERAPEUTIC STRATEGIES, EFFECTS, IMPACTS AND POTENTIAL HAZARDS IN GENERAL. JR [Internet]. 2025 Feb. 7 [cited 2025 May 22];3(1):1-27. Available from: https://journals.4science.ge/index.php/jr/article/view/3393.

42. Sulashvili N, Yaduvanshi U, Yadav M, Gabunia L, Ghambashidze K, Gorgaslidze N, et al. THE SCIENTIFIC DISCOURSE OF FEATURES OF CLINICAL USE AND PHARMACOLOGY OF VASOCONSTRICTORS AND THEIR IMPACT ON CARDIAC FUNCTION. JR [Internet]. 2025 Feb. 21 [cited 2025 May 22];3(1):28-6. Available from: https://journals.4science.ge/index.php/jr/article/view/3414.

43. Nodar Sulashvili, Nana Gorgaslidze, Margarita Beglaryan, Luiza Gabunia, Nato Alavidze, Nino Abuladze, Marina Giorgobiani, Marika Sulashvili, Tamar Okropiridze, and Lali Patsia. 2025. “THE SCIENTIFIC DISCOURSE OF KEY ISSUE ASPECTS OF FEATURES OF CANDIDA PROBLEMS, ANTIFUNGAL DRUGS RESISTANCE CONCERNS, MYCOTOXICOLOGY ISSUES, MYCOECOLOGY, BIOSAFETY RISKS AND EMERGING SOLUTIONS”. Modern Scientific Method, no. 9 (March). https://ojs.scipub.de/index.php/MSM/article/view/5423.

44. Aphkhazava, D., Tuphinashvili, T., Sulashvili, N., & Nozadze, M. (2023). The Features and Role of SHP2 Protein in Postnatal Muscle Development. Scientific Journal „Spectri“, 1. https://doi.org/10.52340/spectri.2023.01

45. SULASHVILI, N., BEGLARYAN, M., GORGASLIDZE, N., KOCHARYAN, S., CHICHOYAN, N., GABUNIA, L., ZARNADZE, S. (DAVIT). (2023). THE DISCLOSURE OF FEATURES, CHARACTERISTICS, POSSIBILITIES AND SPECIALTIES OF CLINICAL PHARMACISTS AS MEDIATOR AMONG DOCTORS AND PATIENTS FOR ENHANCEMENT PUBLIC HEALTH SECTOR IN A GLOBAL WORLD. Experimental and Clinical Medicine Georgia, (4), 57–62. https://doi.org/10.52340/jecm.2023.04.15

46. Sulashvili N, Davitashvili M, Gorgaslidze N, Gabunia L, Beglaryan M, Alavidze N, et al. THE SCIENTIFIC DISCUSSION OF SOME ISSUES OF FEATURES AND CHALLENGES OF USING OF CAR-T CELLS IN IMMUNOTHERAPY. GS 2024 ;6(4):263-90. https://journals.4science.ge/index.php/GS/article/view/3214

47. Aphkhazava, David, Nodar Sulashvili, and Jaba Tkemaladze. 2025. "Stem Cell Systems and Regeneration". Georgian Scientists 7 (1):271-319. https://doi.org/10.52340/gs.2025.07.01.26.

48. Relling, Mary V., and William E. Evans. 2015. "Pharmacogenomics in the Clinic." Nature 526 (7573): 343–50.

49. Aphkhazava, David, Tamar Tuphinashvili, Nodar Sulashvili, and Maia Nozadze. 2023. "THE FEATURES AND ROLE OF SHP2 PROTEIN IN POSTNATAL MUSCLE DEVELOPMENT". Scientific Journal „Spectri" 1 (March). https://doi.org/10.52340/spectri.2023.01.

50. SULASHVILI N, GORGASLIDZE N, GABUNIA L, GIORGOBIANI M, RATIANI L. MANIFESTATION OF THE PARTICULARITIES OF THE USAGE FEATURES OF MONOCLONAL ANTIBODIES IN VARIOUS PHARMACOTHERAPEUTIC APPLICATIONS. jecmg [Internet]. 2023 Nov. 26 [cited 2025 Jul. 12];(4):52-7. Available from: https://journals.4science.ge/index.php/jecm/article/view/2413.

51. Aphkhazava, David, Nodar Sulashvili, Ia Egnatievi, Manana Giorgobiani, Maia Nozadze, Nani Vekua, and Nino Japaridze. 2024. "Derivation of AMPA Receptor GluA1 Subunits in Mice from Exosomes Modulates Inflammatory Pain". Scientific Journal „Spectri" 9 (1). https://doi.org/10.52340/spectri.2024.09.01.05.

52. Aphkhazava, David, Nodar Sulashvili, Ia Egnatievi, Tamar Tupinashvili, and Maia Nozadze. 2024. "DYNAMIC TUMOR MICROENVIRONMENT THEORY: A MULTIFACETED APPROACH TO TUMOR RESEARCH AND BIOCHEMISTRY". Scientific Journal „Spectri" 9 (1). https://doi.org/10.52340/spectri.2024.09.01.06.

53. Sulashvili, Nodar, Irine Pkhakadze, Margarita Beglaryan, Ia Egnatievi, Manana Giorgobiani, Luiza Gabunia, Nana Gorgaslidze, Magda Davitashvili, Ada (Adel) Tadevosyan, and Lali Patsia. 2025. "THE SCIENTIFIC DISCUSSION OF KEY ISSUE ASPECTS OF MODERN ADVANCING INNOVATION OF LEARNING AND TEACHING METHODS AND PEDAGOGICAL APPROACHES IN HIGHER EDUCATION INSTITUTIONS IN MEDICAL EDUCATIONAL STUDY PROGRAMS

DIRECTIONS GLOBALLY IN GENERAL". Scientific Journal „Spectri" 10 (2). https://doi.org/10.52340/spectri.2024.10.01.12.

54. GORGASLIDZE, NANA, NODAR SULASHVILI, LUIZA GABUNIA, LEVAN RATIANI, and MARINA GIORGOBIANI. 2023. "THE SINGULARITIES OF TEMOZOLOMIDE PHARMACOTHERAPEUTIC EFFECTS IN BRAIN TUMOR THERAPEUTIC APPLICATIONS". Experimental and Clinical Medicine Georgia, no. 4 (November):62-66. https://doi.org/10.52340/jecm.2023.04.16.

55. SULASHVILI, NODAR, MARGARITA BEGLARYAN, NANA GORGASLIDZE, SEYRAN KOCHARYAN, NAIRA CHICHOYAN, LUIZA GABUNIA, IRINE ZARNADZE, et al. 2023. "THE DISCLOSURE OF FEATURES, CHARACTERISTICS, POSSIBILITIES AND SPECIALTIES OF CLINICAL PHARMACISTS AS MEDIATOR AMONG DOCTORS AND PATIENTS FOR ENHANCEMENT PUBLIC HEALTH SECTOR IN A GLOBAL WORLD". Experimental and Clinical Medicine Georgia, no. 4 (November):57-62. https://doi.org/10.52340/jecm.2023.04.15.

56. KVIZHINADZE, NATIA, NINO INTSKIRVELI, DAVID TOPURIA, NANA DUGHASHVILI, and NODAR SULASHVILI. 2023. "GSP AND ITS FEATURES IN MEDICAL AND PHARMACEUTICAL INSTITUTIONS ". Experimental and Clinical Medicine Georgia, no. 4 (November):17-19. https://doi.org/10.52340/jecm.2023.04.03.

57. SULASHVILI, NODAR, NANA GORGASLIDZE, MARGARITA BEGLARYAN, LUIZA GABUNIA, NAIRA CHICHOYAN, MARINA GIORGOBIANI, IRINE ZARNADZE, and SHALVA (DAVIT) ZARNADZE. 2022. "THE SCIENTIFIC TALKS OF ESSENTIAL ISSUE, INVOCATION, PERSPECTIVES, INCLINATIONS AND FEATURES OF THE CLINICAL PHARMACISTS GLOBALLY". Experimental and Clinical Medicine Georgia, no. 7 (October). https://doi.org/10.52340/jecm.2022.07.09.

58. SULASHVILI , NODAR, MARGARITA BEGLARYAN, NANA GORGASLIDZE, SEYRAN KOCHARYAN, NAIRA CHICHOYAN, LUIZA GABUNIA, NATIA KVIZHINADZE, MARINA GIORGOBIANI, IRINE ZARNADZE, and SHALVA (DAVIT) ZARNADZE. 2022. "THE SCIENTIFIC DISCUSSION OF SPECIFICITIES OF PHARMACIST OCCUPATIONAL AND HIGHER MEDICAL-PHARMACEUTICAL EDUCATIONAL MANIFESTATION OUTLOOKS IN GEORGIA". Experimental and Clinical Medicine Georgia, no. 7 (October). https://doi.org/10.52340/jecm.2022.07.08.

59. GORGASLIDZE, NANA, SHAFIGA TOPCHIYEVA, MARINA GIORGOBIANI, and NODAR SULASHVILI. 2022. "THE IMPACT OF PHARMACEUTICAL MARKETING ON THE SOCIETY AND INDIVIDUAL PATIENT AND ITS SPECIFICATION OF HANDLING". Experimental and Clinical Medicine Georgia, no. 7 (October). https://doi.org/10.52340/jecm.2022.07.07.

60. GORGASLIDZE, NANA, and NODAR SULASHVILI. 2022. “THE FEATURES OF THE PHARMACEUTICAL MARKET AND ITS OUTLOOKS IN GEORGIA”. Experimental and Clinical Medicine Georgia, no. 7 (October). https://doi.org/10.52340/jecm.2022.07.06.

61. NANA GORGASLIDZE, NODAR SULASHVILI, MARINA GIORGOBIANI, TEA ZARKUA, NANA DUGASHVILI. THE FEATURES OF INSPECTION AND MONITORING FRAMEWORK FOR PROFESSIONAL SAFETY, SANITARY, BIOECOLOGICAL, PREVENTIVE AND HYGIENIC NOVEL REQUIREMENT ISSUES OF PHARMACEUTICAL ORGANIZATIONS IN THE CONTEXT OF THE COVID-19 PANDEMIC IN GEORGIA. jecmg [Internet]. 2021 Oct. 19 [cited 2025 Jul. 12];(5-6):42-6. Available from: https://journals.4science.ge/index.php/jecm/article/view/576.

62. SULASHVILI, NODAR, ARTASHES AZNAURYAN, ANNA TER-MARKOSYAN, NANA GORGASLIDZE, SEYRAN KOCHARYAN, IRINE ZARNADZE, BAGRAT YENOKYAN, et al. 2021. “MODERN SCIENTIFIC DISCUSSION OF SPECIFICITES OF THE ROLE, ACHIEVEMENTS, INNOVATIONS, PROFESSIONAL AND ENHANCEMENT PROSPECTS OF PHARMACISTS IN THE CONTEXT OF THE DEVELOPMENT OF HEALTH CARE SECTOR GLOBALLY”. Experimental and Clinical Medicine Georgia, no. 5-6 (October):38-41. https://journals.4science.ge/index.php/jecm/article/view/575.

63. Aphkhazava, David, Nodar Sulashvili, and Jaba Tkemaladze. 2025. “Stem Cell Systems and Regeneration”. Georgian Scientists 7 (1):271-319. https://doi.org/10.52340/gs.2025.07.01.26.

64. SULASHVILI, NODAR, NANA GORGASLIDZE, LUIZA GABUNIA, LEVAN RATIANI, SHORENA KHETSURIANI, VIRA KRAVCHENKO, IGOR SENIUK, MARINA GIORGOBIANI, NATIA KVIZHINADZE, and MARIKA SULASHVILI. 2024. “MANIFESTATION OF THE PARTICULARITIES OF SOME KEY ISSUE ASPECTS OF NEW IMMUNOTHERAPY CHALLENGES AND PERSPECTIVES BY CAR-T CELL THERAPY”. Experimental and Clinical Medicine Georgia, no. 4 (September):119-21. https://doi.org/10.52340/jecm.2024.04.32.

65. Sulashvili, Nodar, Sharon Fernando, Awad El-Hakeem, Luiza Gabunia, Nana Gorgaslidze, Margarita Beglaryan, Lali Patsia, Natia Kvizhinadze, and Marika Sulashvili. 2025. “CLOSED-LOOP CARDIOPULMONARY BYPASS SYSTEMS WITH REAL-TIME MONITORING AND PHARMACOTHERAPY STRATEGIES: INNOVATIONS, OUTCOMES, CLINICAL IMPACT AND FUTURE DIRECTIONS IN GENERAL”. Georgian Scientists 7 (2):381-419. https://doi.org/10.52340/gs.2025.07.02.36.

66. Sulashvili N, Jadhav RD, Beglaryan M, Gabunia L, Gorgaslidze N, Alavidze N, et al. THE SCIENTIFIC DISCUSSION OF KEY ISSUE ASPECTS OF IMMUNOPATHOGENESIS AND PHARMACOLOGICAL PROPERTIES AND PROFILES IN RELATION TO ADVERSE DRUG REACTIONS CHALLENGES, FOCUS

ON MULTIDIMENSIONAL DRUG-INDUCED EOSINOPHILIA AND SYSTEMIC SYNDROME. GS [Internet]. 2025 Jul. 11 [cited 2025 Jul. 12];7(3):141-79. Available from: https://journals.4science.ge/index.php/GS/article/view/3919.

67. Sulashvili, Nodar, Nato Alavidze, Maka Buleishvili, Vira Kravchenko, Marika Sulashvili, Igor Seniuk, Tamar Okropiridze, Marina Giorgobiani, Lela Grigolia, and Kakhaber Robakidze. 2025. "THE MANIFESTATION OF KEY ISSUE FEATURES OF GLOBAL PERSPECTIVES ON INNOVATIVE TEACHING AND LEARNING APPROACH STRATEGIES IN HIGHER MEDICAL EDUCATION: ADVANCING STUDENT-CENTERED PRACTICES, TECHNOLOGY INTEGRATION AND COMPETENCY-BASED FRAMEWORKS ". Scientific Journal „Spectri" 10 (2). https://doi.org/10.52340/spectri.2024.10.01.11.

68. SULASHVILI, NODAR, NANA GORGASLIDZE, MARGARITA BEGLARYAN, LUIZA GABUNIA, NATIA KVIZHINADZE, TEA ZARKUA, MARINA GIORGOBIANI, NANA PEIKRISHVILI, and MARIKA SULASHVILI. 2024. "THE MANIFESTATION OF CHARACTERISTICS, OPPORTUNITIES AND CHALLENGES OF ELECTRONIC SYSTEMS AND DIGITAL INTELLIGENCE USING IN PHARMACEUTICAL SERVICES". Experimental and Clinical Medicine Georgia, no. 4 (September):122-25. https://doi.org/10.52340/jecm.2024.04.33.

69. Sulashvili N, Davitashvili M, Gorgaslidze N, Gabunia L, Beglaryan M, Alavidze N, et al. THE SCIENTIFIC DISCUSSION OF SOME ISSUES OF FEATURES AND CHALLENGES OF USING OF CAR-T CELLS IN IMMUNOTHERAPY. GS [Internet]. 2024 Nov. 26 [cited 2025 Jul. 12];6(4):263-90. Available from: https://journals.4science.ge/index.php/GS/article/view/3214.

70. Sulashvili, Nodar, Udgam Yaduvanshi, Mohini Yadav, Luiza Gabunia, Ketevan Ghambashidze, Nana Gorgaslidze, Margarita Beglaryan, et al. 2025. "THE SCIENTIFIC DISCOURSE OF FEATURES OF CLINICAL USE AND PHARMACOLOGY OF VASOCONSTRICTORS AND THEIR IMPACT ON CARDIAC FUNCTION". Junior Researchers 3 (1):28-68. https://doi.org/10.52340/jr.2025.03.01.02.

71. Sulashvili N, Nimangre RR. MANIFESTATION OF SOME ASPECTS OF CARDIOVASCULAR DISEASES, IMPLICATIONS, PHARMACOTHERAPEUTIC STRATEGIES, EFFECTS, IMPACTS AND POTENTIAL HAZARDS IN GENERAL. JR [Internet]. 2025 Feb. 7 [cited 2025 Jul. 12];3(1):1-27. Available from: https://journals.4science.ge/index.php/jr/article/view/3393.

72. GORGASLIDZE, NANA, NODAR SULASHVILI, LUIZA GABUNIA, SHAFIGA TOPCHIYEVA, VIRA KRAVCHENKO, MARINA GIORGOBIANI, IRINA ZARNADZE, and IGOR SENIUK. 2024. "MANIFESTATION OF SOME KEY ISSUE ASPECTS OF FEATURES OF MEDICINES TURNOVER AND ITS INFLUENCE ON ENVIRONMENT AND MEDICAL-ECOLOGICAL SAFETY CHALLENGES GLOBALLY". Experimental and Clinical Medicine Georgia, no. 4 (September):130-32. https://doi.org/10.52340/jecm.2024.04.35.

73. SULASHVILI, NODAR, MARGARITA BEGLARYAN, NANA GORGASLIDZE, SEYRAN KOCHARYAN, NAIRA CHICHOYAN, LUIZA GABUNIA, NATIA KVIZHINADZE, et al. 2024. "THE SCIENTIFIC DISCUSSION OF SOME KEY ISSUE ASPECTS OF PHARMACISTS' VOCATIONAL CHALLENGES, VISION, OPPORTUNITIES, OUTLOOKS, OBJECTIONS, APPEARANCES AND INDENTATION IN GENERAL AND PUBLIC HEALTH CARE DIRECTION". Experimental and Clinical Medicine Georgia, no. 4 (September):126-29. https://doi.org/10.52340/jecm.2024.04.34.

74. Aphkhazava, David, Nodar Sulashvili, Tamar Tupinashvili, and Maia Nozadze. 2024. "Dynamic Cellular Equilibrium Theory of Aging: Integrating Maintenance and Accumulation in the Aging Process". Scientific Journal „Spectri"8 (2). https://doi.org/10.52340/spectri.2023.08.02.03.

75. Katsyuba E, Romani M, Hofer D, Auwerx J. NAD^+ homeostasis in health and disease. Nat Metab. 2020;2(1):9–31.

76. Peredo HA, Cardozo J. Parkinson's disease and mitochondrial complex I: a therapeutic target? Biol Res. 2014;47(1):28.

77. Vaarmann A, Mandel M, Zeb A, Wareski P, Liiv J, Kuum M, et al. Mitochondrial biogenesis is required for axonal growth. Development. 2016; 143(11):1981–92.

78. Wang X, Winter D, Ashrafi G, Schlehe J, Wong YL, Selkoe D, et al. PINK1 and Parkin target Miro for phosphorylation and degradation to arrest mitochondrial motility. Cell. 2011; 147(4):893–906.

79. Lautrup S, Amjad HB, Cenini G, Fang EF. NAD^+ in brain aging and neurodegeneration: molecular mechanisms and therapeutic targets. Cell Mol Life Sci. 2023; 80(2):36.

80. Franco-Iborra S, Vila M, Perier C. Mitochondrial quality control in neurodegenerative diseases: focus on Parkinson's disease and Huntington's disease. Front Neurosci. 2018; 12:342.

81. Campello S, Scorrano L. Mitochondrial shape changes: orchestrating cell pathophysiology. EMBO Rep. 2010; 11(9):678–84.

82. Schapira AHV, Chaudhuri KR, Jenner P. Non-motor features of Parkinson disease. Nat Rev Neurosci. 2017; 18(7):435-50.

83. Pickrell AM, Youle RJ. The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease. Neuron. 2015; 85(2):257-73.

84. Bose A, Beal MF. Mitochondrial dysfunction in Parkinson's disease. J Neurochem. 2016;139 Suppl 1:216-31.

85. Titova N, Chaudhuri KR. Personalized medicine in Parkinson's disease: time to be precise. Mov Disord. 2017; 32(8):1147-54.